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The outcomes of recombinant tissue plasminogen activator (rt-PA) for acute ischemic stroke 
among patients with reduced kidney function are uncertain. We conducted a retrospective 
cohort study between 2002-2013 to describe rt-PA use and the risk of secondary intracranial 
hemorrhage (ICH) and disability at discharge. In an overlap weighted cohort of rt-PA eligible 
patients (1,354), the relative risk (RR) of secondary ICH among those who received rt-PA 
(vs. no rt-PA) was 2.56 (99% confidence interval (CI) 1.77-3.69) in those with an estimated 
glomerular filtration rate (eGFR) ≥60, and 2.67 (2.17-6.20) in those with an eGFR 30-59 
mL/min/1.73m2. Those treated with rt-PA were more likely to be discharged alive and 
independent compared no rt-PA (RR ≥60: 1.34 (1.17-1.53), 30-59: 1.53 (1.21-1.93) and, 
<30/chronic dialysis: 2.13 (0.80-5.67)). rt-PA treated patients versus no rt-PA have a higher 
risk of bleeding but also have a greater chance of leaving hospital alive and independent. 
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Summary for Lay Audience 
A commonly used drug to treat a stroke from a blood clot, tissue plasminogen activator, may 
be harmful to those whose kidneys do not work properly. We designed a study to understand 
how this drug treatment is used in people with different levels of kidney function and 
whether it is safe and works well. Among adults living in Ontario, Canada who had an acute 
ischemic stroke, we found that this drug treatment is given to people at all levels of kidney 
function. In a smaller group of people who met the criteria for receiving this treatment, we 
found that patients with normal and reduced kidney function who received the treatment 
were 3 times more likely to bleed into their brains than those who did not receive the 
treatment. At the same time, those who received the treatment were up to 2 times more likely 
to leave the hospital alive with independent function than those who did not receive the 
treatment. Across all levels of kidney function, we conclude that those who did versus did 
not receive treatment are more likely to bleed but also are more likely to leave the hospital 
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Chapter 1  
1 Introduction 
1.1 What is chronic kidney disease? 
Chronic kidney disease (CKD) describes a persistent reduction in kidney function1 and 
affects approximately 13% of the adult Canadian population2. The kidneys are 
responsible for filtering blood of uremic toxins, and a reduction in kidney function results 
in high toxin concentrations in the blood. The level of kidney function is assessed by 
measuring the concentration of serum creatinine (SCr) in the blood and is often described 
as categories of function after converting SCr to an estimated glomerular filtration rate 
(eGFR). These categories range from high or normal (eGFR ≥90 mL/min/1.73m2) to 
kidney failure or end-stage kidney disease (ESKD) (eGFR <15 mL/min/1.73m2).1 To put 
these categories into context, half or more of a patient’s kidney function is lost when their 
GFR is <60 mL/min/1.73m2.3 ESKD is marked by the need for kidney replacement 
therapy (KRT) to sustain life. Current replacement therapies come in the form of chronic 
dialysis treatment (hemodialysis or peritoneal dialysis) or kidney transplantation.  
1.2 Patients with CKD have different vascular risk factors 
than the general population  
Declining kidney function is associated with a high risk of cardiovascular disease and can 
be explained, in part, by traditional risk factors that are common in both cardiovascular 
disease and CKD populations, such as older age, male sex, hypertension and diabetes.4 
The age-standardized rate of cardiovascular events per 100 person-years across categories 
of kidney function is estimated to range from 2.1 among those with an eGFR ≥60 
mL/min/1.73m2 to 36.6 among those with an eGFR <15 mL/min/1.73m2.5 The CKD 
population exhibits a strikingly high risk of stroke. Compared to patients with preserved 
kidney function, in relative terms the risk is 1.5 to 3 times higher across eGFR categories 
and 4 to 10 times higher in patients receiving dialysis.6–10 Evidence suggests the risk of 
stroke increases as kidney function declines across categories of eGFR.11,12 Furthermore, 
studies have estimated that one third or more of the stroke population will have CKD as a 
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comorbid condition13,14 and CKD has been found to be an independent predictor of poor 
outcomes among patients with an acute stroke.13,15–17  
1.3 What is a stroke? 
A stroke is marked by acute neurological dysfunction based on evidence (pathological, 
imaging or other) or clinical evidence of cerebral injury that persists for at least 24 
hours.18  Strokes may be ischemic or hemorrhagic in etiology. Approximately 80% of 
stroke events in the general population are ischemic19–22 and are the result of an occlusion 
in the central nervous system vasculature (either thrombotic or embolic) which obstructs 
the flow of blood and may result in brain cell death. This can lead to a variety of 
cognitive and physical deficits, depending on where the flow of blood is restricted and 
the length of time of the restriction. Hemorrhagic strokes lead to brain tissue death, where 
the bleeding occurs inside the brain itself or just outside in the subarachnoid space. 
Similar to an ischemic stroke, a hemorrhagic stroke can also lead to a variety of deficits 
depending on which part(s) of the brain are affected.18 Both ischemic and hemorrhagic 
strokes present as acute neurological dysfunction with symptoms such as speech 
disturbance, weakness, ataxia (loss of body movement control) and/or headache. 
The risk of death after stroke in the general population is high. The case fatality rate for 
all strokes in Ontario, Canada is 12.6% at 30 days and 22.4% at one-year, and is higher 
among those with an intracranial hemorrhage compared to ischemic stroke.23 In-hospital 
stroke case-fatality is estimated to be 5%, of which 50% is caused by complications from 
stroke.24 
1.4 Risk of ischemic stroke among patients with CKD 
including those receiving dialysis 
Analogous to the general population, there is a higher incidence of ischemic stroke than 
hemorrhagic stroke among patients with CKD. For example, Nickolas et al. found that 
there was a higher percentage of ischemic compared to hemorrhagic (5.8% versus 0.8%) 
stroke among those with reduced kidney function established using SCr laboratory values 
in a multi-ethnic cohort over a follow-up period of 6.5 years.25 Between 1993 and 1998, 
Seliger et al. used the United States Renal Data System to assess stroke type among 
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dialysis patients with a stroke; only 15% were hemorrhagic.7 This trend has also been 
shown in other studies among subgroups of patients receiving dialysis.7,26,27 A study of 
539,287 Swedish residents 30 years of age or older found that declining kidney function 
was associated with an increased hazard of ischemic stroke, with an adjusted hazard rate 
of 1.09 (95% confidence interval (CI)1.04 to 1.14, eGFR 60 to 90), 1.24 (95% CI 1.10 to 
1.34, eGFR 30 to 60), and 2.27 (95% CI 1.63 to 3.17, eGFR 15 to 30) compared to an 
eGFR >90 mL/min/1.73m2.28 Similar results were found in a Dutch study among patients 
over 55 years of age.29 A graded increase in the relative risk of hemorrhagic stroke as 
kidney function declines has also been established.28,30 
One study estimated the one-year rates of death after ischemic stroke to be 11%, 15%, 
and 37% among those with CKD, >60, 45 to 60 and 15 to 44 mL/min/1.73m2, 
respectively. Corresponding estimates after a hemorrhagic stroke were 46%, 36% and 
86%.31 It is important to note that patients with a low eGFR would have a higher 1-year 
risk of death than those with a higher eGFR because they have more comorbidities. 
However, Hoj Fabjan et al. found that after multivariable adjustment eGFR was a 
significant predictor of in-hospital death after ischemic stroke.32 Among the dialysis 
population, the one-year rate of death after dialysis initiation was 18% among those 
without a history of stroke and 40% among those with a prior history of stroke.33 
Combined, these studies demonstrate a trend of higher stroke and stroke-related death 
risks as kidney function declines.  
1.5 Tissue plasminogen activator for the treatment of 
ischemic stroke  
Patients who present to the emergency department with an acute ischemic stroke may be 
eligible for a thrombolytic agent, known as recombinant tissue plasminogen activator (rt-
PA), for treatment of their occlusion.  
1.5.1 What is rt-PA? 
Tissue plasminogen activator is an enzyme involved in the breakdown of blood clots. 34,35 
The manufactured biosynthetic version of this enzyme, rt-PA,34–37 is commonly referred 
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to as alteplase (generic drug name). rt-PA is cleared through the liver.35,38 Multiple 
randomized controlled trails (RCTs) have tested the safety and efficacy of rt-PA versus 
placebo for acute ischemic stroke in the general population, and a Cochrane review and 
meta-analysis of these controlled trials (total n = 7,012) found a significant reduction in 
morbidity with the use of rt-PA.39,40 The odds ratio of being alive and independent at final 
follow-up (4 weeks to 6 months) among those who were given rt-PA up to six hours after 
symptom onset in 12 trials was 1.17 (95% CI 1.06 to 1.29) compared to those who did 
not receive rt-PA therapy. The magnitude of benefit increased in a subgroup of patients 
who received rt-PA within three hours of symptom onset [odds ratio of 1.53 (95% CI 
1.26 to 1.86)]. The odds ratio of death in the rt-PA treatment group compared to placebo 
seven days after symptom onset was 1.44 (95% CI 1.18 to 1.76), but this effect was 
attenuated and no longer significant at the end of follow-up (1.06, 95% CI 0.94 to 1.20) 
(range from four to six months).40 However, rt-PA also comes with a risk of intracranial 
hemorrhage. An ICH manifests similarly to a hemorrhagic stroke but etiologically it is a 
hemorrhagic conversion of the cerebral infarct resulting from rt-PA therapy.41 Clinical 
presentation can be marked by rapid deterioration of a patient’s clinical state but not all 
are symptomatic. It is estimated that up to 40% of patients with symptomatic ICH may 
have poor outcomes, such as disability and death, as a result of continued bleeding post 
rt-PA therapy.42 Wardlaw et al. (2012) found that the odds ratio of symptomatic 
intracranial hemorrhage (hemorrhagic conversion of the infarct that manifests symptoms) 
was 3.72 (95% CI 2.98 to 4.64) in the rt-PA treatment group (up to 6 hours after the 
stroke) compared to control at 7 days from symptom onset. The odds ratios were 
amplified when looking at the subgroup of patients who received rt-PA therapy vs. 
control within 3 hours of the stroke to 4.55 (95% CI 2.92 to 7.09). Acknowledging the 
high odds ratio of symptomatic intracranial hemorrhage, the conclusion of the Cochrane 
review was that there is an overall net benefit in independence and mortality among those 
who receive thrombolytic therapy in highly selected patients.40 One of the major 
limitations of the trial data is that the safety and efficacy of rt-PA was assessed in a 
narrow range of patients who had a limited number of comorbidities.39  
The Canadian Alteplase for Stroke Effectiveness Study (CASES) was essential for the 
licensure of rt-PA for the treatment of acute ischemic stroke in Canada.43 Sixty centres 
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across the country including 1,135 patients participated in the study. Investigators found 
that 37% of patients experienced a return to their pre-stroke functioning with rt-PA 
treatment and 22% (95% CI 20.0 to 25.0) died within 90 days. These outcome 
frequencies aligned with the NINDS rt-PA Stroke Study.44 Symptomatic ICH occurred in 
5% (95% CI 3% to 6%) of the participants who received rt-PA, of which 75% died in 
hospital. This rate of symptomatic ICH was lower than that seen in clinical trials.43  
rt-PA is the standard of care in Canada for the treatment of acute ischemic stroke in 
patients who meet inclusion criteria45 and it is the only approved thrombolytic treatment 
for acute ischemic stroke available in the United States 40 and Canada45. In order to 
minimize the risk of secondary ICH, criteria have been established to guide physicians in 
determining which patients will most benefit from receiving rt-PA therapy.   
1.5.2 Who can receive rt-PA as a treatment for ischemic stroke? 
The Canadian Stroke Best Practices Recommendations for Acute Ischemic Stroke 
Treatment outline the criteria for acute thrombolytic therapy; listing the inclusion and 
exclusion criteria for receiving rt-PA including age, time from stroke symptom onset and 
hemorrhage on brain imaging (a full list of the criteria can be found in Appendix A).46,47 
The recommendations are developed using Practice Guideline Evaluation and Adaptation 
methodology48,49 by a multi-disciplinary group of leaders and experts.50 Front-line 
physicians who treat patients with ischemic stroke can use these recommendations to 
guide acute management of ischemic stroke. The acute thrombolytic therapy 
recommendations were first published in 2006 and have gone through minor updates over 
the years.  
Reduced kidney function is not listed as a contraindication for rt-PA therapy as it was not 
an exclusion criterion in any of the clinical trials of rt-PA.51,52 Furthermore, the Canadian 
Stroke Best Practice Recommendations for Hyperacute Stroke Care does not provide a 
recommendation based on kidney function in the guidelines.50 In light of this, it is not 
clear whether patients with reduced levels of kidney function are treated with rt-PA 
similarly to those with normal kidney function. One particularly broad exclusion, “Any 
source of active hemorrhage or any condition that could increase the risk of major 
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hemorrhage after rt-PA administration” in the Canadian guidelines, may impact a 
physician’s decision to treat a patient with CKD.46 This is predicated on the notion that 
physicians who treat patients with ischemic stroke are aware of the general bleeding risks 
associated with decreased kidney function.28,53–62 The three-year cumulative incidence of 
major hemorrhage, defined as a hospitalization for intracranial or gastrointestinal 
hemorrhage, was significantly higher (4.6 %) among those with moderate kidney 
function to kidney failure compared to those with high to mildly decreased kidney 
function (1.0 %). Furthermore, there was a dose response relationship, as kidney function 
declined the incidence of major hemorrhage increased, with a cumulative incidence 
ranging from 0.7% among those with high to normal function to 12% among those with 
ESKD.53 In a study of patients initiating chronic dialysis, the three-year cumulative 
incidence of major hemorrhage was 14%55 and continued to persist among those who 
received a kidney transplant, 4%, although the incidence was attenuated63.  
In stratified analysis of the three-year risk of major hemorrhage in patients in Ontario, 
investigators found an increased crude relative risk of hemorrhagic stroke across all 
categories of eGFR when compared to those with high to normal kidney function, 
ranging from 2.2 (95 % CI 2.0 to 2.5) to 13.5 (95% CI 11.5 to 15.8).53 The high risk of 
major hemorrhage in the kidney disease population has been replicated in many studies 
across geographical areas.54,57–62,64 
Based on this evidence, there is reason to hypothesize that patients with reduced kidney 
function may also have different bleeding risks after rt-PA therapy than the general 
population that participated in the original rt-PA RCTs. This makes the overall benefit – 
risk considerations for the use of rt-PA in patients with reduced kidney function 
uncertain.  
1.5.3 The real-world use of rt-PA across categories of CKD 
The use of rt-PA may differ among the general population and those with CKD. In two 
separate surveys of opinion among nephrologists and experts in thrombolytic therapy for 
acute stroke, both groups reported concern over the bleeding risk after rt-PA therapy 
among patients with reduced kidney function.65,66 The utilization of rt-PA and the reasons 
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for withholding treatment across stages of real function have not been described 
previously.  
The real-world safety and effectiveness of rt-PA in the CKD and dialysis population who 
received rt-PA therapy have been investigated in several international observational 
studies3,51,52,67–76, some of which have been pooled in a meta-analysis77. The largest and 
most comprehensive study is that done by Ovbiagele et al. who estimated the odds ratio 
of serious systemic hemorrhage, in-hospital mortality and functional status (no 
independent ambulation at discharge) across categories of kidney function in 44,410 
patients who suffered ischemic stroke and received rt-PA.78 Compared to patients without 
CKD, those with CKD did not exhibit an increased adjusted odds ratio of symptomatic 
ICH (adjusted OR 1.0, 95% CI 0.91 to 1.10). In other words, the incidence of 
symptomatic ICH within 36-hours after rt-PA did not vary by kidney function category. 
Patients with ischemic stroke who received rt-PA and had CKD, compared to those who 
received rt-PA and did not have CKD, were more likely to have an unfavourable 
functional status at discharge (adjusted OR 1.13, 95% CI 1.07 to 1.19) and die in-hospital 
(adjusted OR 1.22, 95% CI 1.14 to 1.32). In the adjusted analyses, both functional 
outcomes and in-hospital death showed statistically higher odds ratio in those with 
reduced kidney function (eGFR <30) compared to those with normal or high kidney 
function (eGFR ≥90).78 
The remainder of the observational studies show mixed estimates of the odds ratio of 
secondary intracranial hemorrhage, poor outcome, and death among those who received 
rt-PA therapy comparing those with an eGFR <60 mL/min/1.73m2 to those with an eGFR 
≥60 mL/min/1.73m2.3,67,70,73–77,79–85 To-date, no RCT assigning treatment to rt-PA therapy 
versus placebo has been done in the CKD population to understand the risk and benefit of 
therapy. Furthermore, a comparison of the risks and benefits of rt-PA exposure in a real-
world setting (observational study) in the CKD population has not been done.  
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Chapter 2  
2 Objectives and hypotheses 
Our first objective was to describe acute ischemic stroke characteristics comparing those 
who received rt-PA therapy to no therapy within categories of eGFR, and to describe the 
variation of these characteristics across eGFR categories. Additionally, we sought to 
describe the treatment characteristics among patients who received rt-PA across eGFR 
categories. We hypothesized that those who received rt-PA therapy compared to those 
who did not, would present to the hospital earlier and would have more severe strokes. 
As eGFR declined, time from symptom onset to hospital arrival would decrease and 
stroke severity would increase.  
Our second objective was to determine rt-PA therapy eligibility among patients who had 
an acute ischemic stroke by eGFR category using administrative and research databases. 
We hypothesized that most patients would be ineligible for rt-PA therapy, and 
ineligibility would increase as kidney function declined. 
Our third objective was to estimate the absolute and relative risk of secondary intracranial 
hemorrhage (ICH) and disability at hospital discharge among those eligible to receive rt-
PA therapy after they suffered an acute ischemic stroke, comparing patients who received 
rt-PA therapy to no therapy within categories of eGFR. Furthermore, we wanted to 
determine if the relative risk of our outcomes were modified across eGFR categories in 
absolute and relative terms. We hypothesized that those who received rt-PA compared to 
those who did not would have a higher relative risk of bleeding but a lower relative risk 
of disability at discharge within all categories of eGFR. Furthermore, across categories of 
declining baseline kidney function, there would be a graded absolute increase in the 
relative risk of secondary ICH with vs. without rt-PA (a harm of treatment), accompanied 
by a graded absolute increase in the chance of being discharged alive from hospital with 
independent function (a benefit of treatment).  
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Chapter 3  
3 Methods 
3.1 Study design and setting 
We designed a retrospective cohort of adults (≥18 years of age) with ischemic stroke in 
Ontario, Canada. We included patients who had an acute hospital admission for an 
ischemic stroke between April 1, 2002 and March 31, 2013. Patients were followed from 
their hospital arrival for one-year. To capture episodes of ischemic stroke care, we used 
linked administrative and research databases held at ICES. The use of data in this project 
was authorized under section 45 of Ontario’s Personal Health Information Protection Act, 
which does not require review by a Research Ethics Board. The reporting of this 
observational study adheres to Reporting of studies conducted using observational 
routinely-collected health data (RECORD) guidelines (Appendix B).86  
3.2 Patients 
Patients were eligible if they had a discharge diagnosis of ischemic stroke in the Ontario 
Stroke Registry (OSR) database. The OSR is a registry designed for the measurement and 
monitoring of stroke care in Ontario and consists of two overlapping data collection 
methods. The Ontario Stroke Audit (OSA) is a population-based retrospective chart 
extraction project that collected a sample of cases approximately every two years 
between 2002 and 2013. The Regional Stroke Centre (RSC) data was a combination of 
prospective and retrospective ascertainment of cases at the regional stroke centres 
between 2001 and 2012. The registry is made up of a population-based sample of patients 
with suspected stroke and transient ischemic attack seen in an emergency department or 
admitted to an acute hospital in the province (see Appendix C for detailed sampling 
strategies). The OSR is a database held at ICES and is linked to other administrative 
datasets including the Registered Persons Database, the Canadian Institute for Health 
Information Discharge Abstract Database, the Ontario Health Insurance Plan, and the 
Canadian Organ Replacement Register (CORR). These datasets were linked using unique 
encoded identifiers and analyzed at ICES. Patients were excluded from our study based 
on the following criteria: 1) missing age, sex, ICES unique identifier, or were not an 
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Ontario resident (data cleaning), 2) evidence of death before the index date (suggesting 
data entry error), 3) missing baseline serum creatinine measurement (which is needed to 
determine baseline kidney function), 4) missing international normalized ratio (INR) 
measurement at admission (key covariate), 5) missing glucose measurement at admission 
(key covariate), 6) missing time from hospital arrival to imaging (key covariate), 7) 
history of hemi, para or quadriplegia (as this impacts their access to rt-PA), 8) received 
stroke care at a non-designated hospital (as this impacts their access to rt-PA therapy), 
evidence of an in-hospital stroke (as we are unable to determine their baseline kidney 
function). If patients had multiple events, we restricted to the first event available in the 
OSR. The index date was the date of arrival to hospital.  
3.3 Exposure 
The exposure was treatment with rt-PA therapy (yes/no) as recorded in the OSR. Results 
were reported by baseline kidney function estimated using the first serum creatinine 
documented at the time of hospital presentation for the stroke (usually done in the 
emergency department) and converted to an estimated glomerular filtration rate (eGFR) 
using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation 
(Appendix D).87 We tested the stability of this laboratory value in a subgroup of patients 
with a prior pre-hospitalization outpatient serum creatinine laboratory measurement and 
found to it had substantial agreement within eGFR categories (see Appendix E for 
details). eGFR was categorized, as normal, high or mildly decreased, ≥60 
mL/min/1.73m2, moderately decreased, 30-59 mL/min/1.73m2, severely decreased and 
kidney failure, <30 mL/min/1.73m2, using modified cut-points of eGFR described in the 
Kidney Disease Improving Global Outcomes (KDIGO) guidelines.1 Chronic dialysis was 
defined using CORR and these patients were grouped within the KDIGO severely 
decreased and kidney failure category (eGFR <30 mL/min/1.73m2).  
3.4 Outcomes 
The primary outcomes were secondary ICH and disability at discharge. Secondary ICH 
could occur at any time within the hospital admission for stroke and was captured by 
subsequent neuroimaging after the initial admission brain scan. The definition includes 
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both symptomatic and asymptomatic secondary ICH and was captured using the OSR and 
supplemented with the Discharge Abstract Database. Disability was measured using the 
modified Rankin scale (mRS) at discharge in the OSR. The mRS is a scale for the 
measurement of the degree of disability (0 to 6) based on daily activities after stroke.88 
For the purposes of our analyses, we made the mRS binary (categorized as 0-2 yes/no) 
which captures those who were alive and independent at discharge. Our secondary 
outcomes were death in-hospital, at 30 days and 1-year from the time last seen normal, 
and systemic hemorrhage. The administrative codes used to define each of the exposure 
and outcome variables can be found in Table 1.  
3.5 Statistical methods 
3.5.1 rt-PA and ischemic stroke characteristics  
Baseline characteristics are reported by those who received rt-PA and those who did not 
(control) within three categories of eGFR. Continuous variables were reported as medians 
and interquartile ranges (25th, 75th percentiles) and categorical variables are reported as 
frequencies and percentages. Standardized differences were used to estimate between-
group differences in baseline characteristics, where a difference ≥10% is considered 
statistically significant.89,90 The concept definitions for the baseline variables can be 
found in Appendix F. An exploratory analysis was conducted to estimate the percentage 
of patients with ischemic stroke presenting to the hospital with a concurrent acute kidney 
injury (AKI) (details of these analyses can be found in Appendix G).  
3.5.2 rt-PA eligibility criteria 
Based on Canadian stroke guidelines and previous RCT eligibility criteria, patients were 
assessed on their eligibility to receive rt-PA based on 15 criteria using baseline 
administrative and registry data. The detailed criteria used to assess eligibility can be 
found in Appendix H. There were some stroke eligibility criteria that could not be 
estimated using available datasets. These criteria, based on best practice guidelines, were 
(1) “Any other condition that could increase the risk of hemorrhage after rt-PA 
administration”, (2) “Elevated partial thromboplastin time”, (3) “CT showing early signs 
of extensive infarction, represented by a score of less than five on the Alberta Stroke 
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Program Early CT Score (ASPECTS), or MRI showing an infarct volume greater than 
150 cc on diffusion-weighted imaging”, (4) “Arterial puncture at a non-compressible site 
in last 7 days” and (5) “Rapidly improving symptoms”.46  
rt-PA eligibility criteria were applied to all the patients in our cohort. Patients were 
categorized as either eligible or ineligible for rt-PA therapy based on these criteria. We 
calculated the frequency and percentage of patients in each eligibility group within 
categories of eGFR to understand if eligibility changed by kidney function category. We 
also estimated the reliability of our administrative-based eligibility criteria compared to 
the real-world frequency of rt-PA administration based on chart review, i.e. patients who 
received rt-PA in the OSR. We calculated percent agreement, Cohen’s simple kappa, p-
values and 95% confidence intervals. We also reported the reasons rt-PA was not given 
among those who did not receive rt-PA using the OSR data. For secondary ICH and 
disability risk analyses (objective 3), we restricted the cohort to those who were eligible 
to receive rt-PA.  
3.5.3 Primary and secondary outcomes  
To estimate the relative risk of secondary ICH and disability at discharge by rt-PA 
exposure we estimated a patient’s propensity score for receiving rt-PA using logistic 
regression. This was done separately for each eGFR category by rt-PA exposure. 
Propensity score is a statistical method that balances baseline characteristics between two 
groups in an effort to reduce systematic differences and mimic the conditions of a RCT. 
The propensity score is the predicted probability that each patient will receive the 
exposure given their measured covariates. Using a logistic regression model, treatment 
status is regressed on baseline characteristics to create similar distributions among 
patients with the same propensity score.91 Baseline characteristics that were unbalanced 
were included in our propensity score model. The characteristics used in each propensity 
score model varied across eGFR categories and the exact variables included in each 
model are outlined in Appendix I. Simple imputation was used for baseline 
characteristics with <10% missing. The distribution of propensity scores (Appendix J) 
showed a large number of patients with extreme values in the tails. In light of this, we 
applied overlap weighting which estimates the probability of being assigned to the 
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opposite exposure group. This method reduces the influence of individuals in the tails of 
the propensity score distribution without excluding them and up-weights individuals with 
a higher likelihood of receiving either treatment.92 Subsequently, the overlap weighted 
propensity score exposure group distributions looked similar between rt-PA exposure 
groups (Appendix J). Within each category of eGFR, exposure groups were weighted 
such that 50% of the patients were in each group. To assess the overlap weighting 
balance, baseline characteristics were compared between the weighted exposure groups 
within each category of eGFR. The frequency, percentages and standardized differences 
reported were weighted and rounded for ease of interpretation. The relative risk of 
secondary ICH, being alive and independent  and our secondary outcomes within eGFR 
categories were estimated using modified Poisson regression.93 Some patients (13%) 
were removed from the mRS analysis due to missing data or because they died in-
hospital. 
Ninety-nine percent confidence intervals (α= 0.01) were used to account for multiple 
comparisons across eGFR categories. We estimated the risk difference and number 
needed to treat/harm (NNT/NNH) for all outcomes. All results were estimated within the 
modified version of the KDIGO eGFR categories (≥60 mL/min/1.73m2, 30-59 
mL/min/1.73m2 and <30 mL/min/1.73m2 or on chronic dialysis) due to small sample size 
among those with kidney failure. Often the percentages of our outcome were >10% so we 
also estimated the odds ratio (OR) for comparison with the literature. We estimated the 
multiplicative and additive interaction across eGFR categories, where an eGFR ≥60 
mL/min/1.73m2 was the reference group. Multiplicative interaction was estimated using 
the log of the relative risk point estimates for each outcome,94 and additive interaction 
was estimated using the proportion of outcomes by rt-PA exposure.95 The E-value was 
also estimated in a sensitivity analysis for each outcome to better understand residual 
confounding. The E-value is the minimum strength of association that an unmeasured 
confounder would need to explain away the observed effect estimate.96  
A sensitivity analysis was done to account for pre-event independence in the mRS 
outcome. We created a subgroup of patients who were independent or had a slight 
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disability prior to the ischemic stroke event and repeated the RR analysis within eGFR 
categories.  
Analyses for our systemic hemorrhage secondary outcome were abandoned after we 
found a small number of events within all categories of eGFR. Due to ICES privacy 
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Chapter 4  
4 Results 
There were 44,659 patients with an acute ischemic stroke in the OSR. Based on pre-
specified criteria, we excluded 22,250 patients (see Figure 1 flow diagram), leaving 
22,409 patients in the study cohort.  
4.1 Acute ischemic stroke characteristics according to rt-PA 
therapy by eGFR category   
In our cohort of 22,409 patients, 4,013 (18%) were treated with rt-PA. Across eGFR 
categories, the proportion who received rt-PA was 18% with an eGFR ≥60 
mL/min/1.73m2, 19% with an eGFR 30-59 mL/min/1.73m2, and 14% with an eGFR <30 
mL/min/1.73m2 or on chronic dialysis (Table 2). The documented reasons that rt-PA was 
not given to patients can be found in Appendix K.  
Most patients (51%) arrived at the hospital within 4.5 hours of ischemic stroke symptom 
onset. Within this group, 34% received rt-PA, compared to 1% of those who presented to 
hospital beyond 4.5 hours. Among those who arrived at the hospital within 4.5 hours 
across the eGFR categories, the proportion who received rt-PA declined as eGFR 
declined. 
Most patients (81%) presented with weakness, but less than 22% of those with weakness 
received rt-PA. Across eGFR categories, the proportion of patients with weakness who 
received rt-PA was slightly lower in those with an eGFR <30 or on chronic dialysis 
(17%) compared to the other eGFR categories (21%). 
The National Institute for Stroke Scale (NIHSS) is an assessment tool that quantifies a 
patient’s level of stroke impairment. rt-PA was administered more frequently to those 
with moderate to severe strokes (NIHSS ≥5) compared to those with no symptoms or 
minor strokes (NIHSS <5). However, most patients (80%) in all NIHSS categories did 
not receive rt-PA therapy. Across eGFR categories, among those with moderate to severe 
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strokes (NIHSS ≥5) rt-PA administration declined as eGFR declined. This is despite 
evidence that the median stroke severity score increased across lower eGFR categories. 
Most patients (80%) had a brain scan within 3.5 hours of hospital arrival and within this 
group, 22% received rt-PA. Across eGFR categories, the proportion of patients who 
received a brain scan and rt-PA was slightly lower in those with an eGFR <30 or on 
chronic dialysis (18%) compared to the other eGFR categories (22%). 
Of those who received rt-PA therapy (4,013), most (>96%) received this therapy within 
3.5 hours from stroke symptom onset. The time between stroke symptom onset and 
receipt of rt-PA therapy was similar as eGFR category declined (Table 3).   
Most patients were administered rt-PA therapy intravenously (compared to intra-
arterially) and the percentage of patients who received intravenous vs. intra-arterial rt-PA 
increased as eGFR category declined (from 93% to 97%). Among those who received 
intravenous rt-PA, the median dose was higher in those with an eGFR ≥60 
ml/min/1.73m2 compared to the other two eGFR categories (68 mg vs. 63 mg).   
4.2 The proportion of patients with ischemic stroke who 
were eligible to receive rt-PA treatment by eGFR 
category  
Using eligibility criteria established in the RCTs testing rt-PA vs. placebo and the 
Canadian Stroke Best Practice Recommendations, we assessed eligibility for rt-PA of 
each patient with an ischemic stroke event in our cohort (22,409). Eligibility was 
assessed according to characteristics recorded within our administrative and research 
databases. In Table 4, we report the frequency and percentage of patients who were 
eligible or ineligible for each criterion when assessed independently (i.e. not unique). A 
large number of patients were found to be ineligible based on the following criteria: 
hospital arrival time >4.5 hours after symptom onset (49%), blood pressure >185/110 
mm/Hg (19%), and mild stroke (NIHSS ≤4) (34%).  
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When we accounted for all the eligibility criteria, 4,632 of 22,409 patients (21%) were 
eligible for rt-PA therapy. The percentage of patients who were rt-PA eligible was 
consistent across eGFR categories: 2,711 of 13,214 (21%) with an eGFR ≥60 
mL/min/1.73m2 were rt-PA eligible, and corresponding proportions in those with an 
eGFR between 30 and 60, and <30 mL/min/1.73m2 including those receiving dialysis 
were 1,629 of 7,735 (21%), and 292 or 1,460 (20%), respectively.  
We measured the reliability of our eligibility criteria definition using administrative and 
research databases by comparing it to those who received rt-PA therapy in the real-world. 
The percent agreement between the two measures was 89.9% (95% CI 85.5 to 86.4). 
When we estimated Cohen’s simple kappa, we found a coefficient of 0.55 (95% CI, 0.54 
to 0.56) suggesting moderate agreement. For the remainder of the study analyses, we 
excluded all patients who did not meet all the eligibility criteria outlined above leaving 
4,632 patients eligible to receive rt-PA.   
4.3 Characteristics of ischemic stroke in patients eligible to 
receive rt-PA by rt-PA treatment status and eGFR 
category  
In patients eligible to receive rt-PA (4,632), rt-PA therapy was administered to 39% 
(1,049 of 2,711) of those with a baseline eGFR ≥60 mL/min/1.73m2, 41% (670 of 1,629) 
in those with an eGFR of 30-59, and 55% (161 of 292) in those with an eGFR of <30 or 
on chronic dialysis.   
In patients eligible to receive rt-PA, patient characteristics according to whether they 
received rt-PA or not and by eGFR category is presented in Table 5. We initially focused 
on examining the characteristics of those who did and did not receive rt-PA within 
categories of eGFR, and then compared those who did and did not receive rt-PA across 
eGFR categories.   
The median age of patients who received rt-PA was 71, 80 and 81 in eGFR categories 
≥60, 30-59 and <30 mL/min/1.73m2 or on chronic dialysis, respectively. The median age 
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of those who did not receive rt-PA therapy was 67, 82 and 84, respectively. Most patients 
who received rt-PA with normal to high kidney function (eGFR ≥60) were male (59%), 
whereas most patients with decreased kidney function were female (57% with an eGFR 
30-59, and 63% with an eGFR <30 or on chronic dialysis). Similar results were found 
among those who did not receive rt-PA; there were more males among those with an 
eGFR ≥60 (59%) and more females with an eGFR 30-59 (59%) and <30 or on chronic 
dialysis (57%).  
Of those with pre-event independence data (2,642), 36%, 44% and 17% of the rt-PA 
group were independent prior to their stroke event by eGFR ≥60, 30-59 and <30 or on 
chronic dialysis category, respectively. In the group who did not receive rt-PA therapy, 
55%, 24% and 36% were independent. Pre-event independence missingness ranged from 
36% to 52% of the rt-PA eligible cohort.  
The median NIHSS of patients who received rt-PA was 7, 12 and 14 in eGFR categories 
≥60, 30-59 and <30 or on chronic dialysis, respectively. The median NIHSS of those who 
did not receive rt-PA therapy was 11, 8 and 10, respectively.  
Of those who received rt-PA and those who did not, most patients (>65%) had a Charlson 
Comorbidity Index of 0-1 in eGFR categories ≥60 and 30-59. However, the majority of 
patients with an eGFR <30 or on chronic dialysis had a Charlson score ≥2 in both rt-PA 
therapy groups (>59%). Comorbidities such as diabetes, hyperlipidemia, coronary artery 
disease and stroke were high in rt-PA eligible cohort and were more frequent among 
those who did not receive rt-PA therapy compared the rt-PA therapy group in those 
whose eGFR was <60 mL/min/1.73m2.  
Most patients with an eGFR ≤60 mL/min/1.73m2 or on chronic dialysis had a high risk of 
bleeding score (HASBLED ≥3) in both rt-PA and no rt-PA groups at baseline (>52%).   
Across eGFR categories, both age and the percentage of females increased as eGFR 
deceased in those who received rt-PA and those who did not. Diabetes, hyperlipidemia, 
coronary artery disease and a high risk of bleeding score (HASBLED ≥3) also increased 
as eGFR declined in both exposure groups (rt-PA and no rt-PA). Both rt-PA therapy 
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groups showed an increase in slight to severe pre-event disability as eGFR declined. In 
those who received rt-PA therapy, the median NIHSS increased as eGFR declined but 
among those who did not receive rt-PA these scores decreased with declining eGFR. 
Additional baseline characteristic results can be found in Appendix L.   
4.4 Weighted baseline characteristics by rt-PA therapy 
exposure and eGFR category 
After overlap weighting on the propensity score, there was a total of 1,354 patients in our 
cohort, with 804 (59%), 492 (36%) and <64 (<5%) patients in eGFR categories ≥60, 30-
59 and <30 or on chronic dialysis, respectively (Table 6). After overlap weighting, those 
who received rt-PA vs. those who did not were well balanced within categories of eGFR 
on all baseline characteristics. A table of all the weighted baseline characteristics can be 
found in Appendix M.   
4.5 Risk of secondary ICH by rt-PA exposure within 
categories of eGFR 
Secondary ICH occurred in 14% of patients with an eGFR ≥60, 15% with an eGFR 30-
59, and 16% with an eGFR <15mL/min/1.73m2 or on chronic dialysis who received rt-
PA therapy (weighted) (Figure 2a). The percentage of secondary ICH was higher in those 
treated with rt-PA vs. those who did not receive rt-PA. The weighted absolute risk 
increase of secondary ICH with rt-PA vs. no rt-PA was 9% in those with an eGFR ≥60 
mL/min/1.73m2 (number needed to harm (NNH) 12 patients treated with rt-PA), 11% 
(NNH 10 patients), and 16% (NNH 6 patients) in those with an eGFR 30-59 
mL/min/1.73m2 and <30 mL/min/1.73m2 or on chronic dialysis, respectively (positive 
additive interaction p-value=0.02). In a descriptive subgroup analysis, we estimated the 
weighted frequency of secondary ICHs that were symptomatic (clinically detectible 
neurological deterioration). We found 47% of ICHs among those with an eGFR of ≥60 
were symptomatic. Corresponding numbers for an eGFR 30-59, and <30 or on chronic 
dialysis, were 44% and 25%, respectively.   
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In relative terms, receiving rt-PA therapy (vs. no therapy) was associated with a higher 
relative risk of secondary ICH among patients with an eGFR ≥60 (weighted relative risk 
(RRw) 2.56, 99% confidence interval (CI) 1.77 to 3.69) and those with an eGFR 30-59 
(RRw 3.67, 99% CI 2.17 to 6.20). The magnitude of this risk did not significantly differ 
between the groups (p-value for interaction 0.42) (Figure 3). We were unable to fit the 
weighted relative risk model within the eGFR <30 or on chronic dialysis category due to 
a small number of events. In addition to relative risk we also estimated the weighted odds 
ratio of secondary ICH by eGFR category and these results can be found in Appendix N.  
We assessed the robustness of this association and found the E-values estimating the 
strength of the weighted relative risk association that an unmeasured confounder would 
need to explain the effect of rt-PA on secondary ICH were 4.56 and 4.78 (≥60 and 30-59, 
respectively) (see Appendix O for E-value figures).    
4.6 Disability at hospital discharge 
In those who received rt-PA, the chance of leaving the hospital alive with independent 
function (mRS 0-2) was 45% in those with an eGFR ≥60, 33% with an eGFR 30-59, and 
16% with an eGFR <15mL/min/1.73m2 or on chronic dialysis (weighted) (Figure 2b). In 
those who did not receive rt-PA, the chance of leaving hospital alive with independent 
function was 34% in those with an eGFR ≥60, and 22% and 8% in those with an eGFR 
30 to 59 and <30 or on chronic dialysis, respectively.  
Receipt of rt-PA (vs. no rt-PA) resulted in a better chance of leaving hospital alive with 
independent function across all eGFR categories. The weighted absolute risk differences 
were 11% (NNT 9 patients treated with rt-PA) among patients with an eGFR ≥60, 12% 
(NNT 9 patients) among patients with an eGFR 30-59, and 9% (NNT 12 patient) for 
those with an eGFR <30 or on chronic dialysis. A positive additive interaction (p-
value=0.001) was found comparing disability at discharge among patients who received 
rt-PA vs. those who did not with eGFRs ≥60 to 30-59 mL/min/1.73m2, and a negative 
interaction (p-value= -0.03) among patients with eGFRs ≥60 to <30 mL/min/1.73m2 or 
on chronic dialysis.  
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Receiving rt-PA therapy was associated with a weighted relative risk of being discharged 
alive and independent of 1.34 (99% CI 1.17 to 1.53) in those with an eGFR ≥60, 1.53 
(99% CI 1.21 to 1.93) in those with an eGFR 30-59, and 2.13 (99% CI 0.80 to 5.67) in 
those with an eGFR <30 or on chronic dialysis, compared to those who did not receive rt-
PA therapy (Figure 3). When we compared the weighted relative risk of being discharged 
alive and independent comparing patients on their use of rt-PA therapy by eGFR category 
(≥60 vs. 30-59, ≥60 vs. <30 or chronic dialysis), we did not find a significant interaction 
effect.  
When we assessed the robustness of this association, the E-values estimating the strength 
of the weighted relative risk association that an unmeasured confounder would need to 
explain the effect of rt-PA on disability are 2.01, 2.43 and 3.68 (≥60, 30-59 and <30 or on 
chronic dialysis, respectively) (see Appendix O for E-value figures).    
In a sensitivity analysis, we estimated the weighted relative risk in a subgroup of patients 
who were independent or had a slight disability prior to their stroke event and found that 
being discharged alive and independent was 1.16 (99% CI 0.98 to 1.36) times higher 
among those who received rt-PA and had an eGFR ≥60. Among those with an eGFR <30 
or on chronic dialysis, the relative risk of being discharged alive and independent was 
0.87 (99% CI 0.19 to 4.06) times lower for those who received rt-PA therapy. There was 
no difference in the relative risk among patients with an eGFR 30-59 (1.01, 99% CI 0.77 
to 1.33).  
4.7 Death in-hospital, 30 days and one-year 
Death in-hospital occurred in 9% of those with an eGFR ≥60, 15% with an eGFR 30-59, 
and 18% with an eGFR <30 or on chronic dialysis who received rt-PA therapy (weighted) 
(Figure 2c). In those who did not receive rt-PA, death occurred in 12% in those with an 
eGFR ≥60, and 14% and 23% in those with an eGFR 30 to 59 and <30 or on chronic 
dialysis, respectively.  
The weighted absolute risk difference was 2% (NNT 44 patients treated with rt-PA), 1% 
(NNT 112 patients) and 5% (NNT 20 patients) among eGFR categories ≥60, 30-59 and 
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<30 or on chronic dialysis, respectively. A positive additive interaction (p-value=0.03) 
was found comparing in-hospital death among patients who received rt-PA vs. those who 
did not with eGFRs ≥60 to 30-59, and a negative interaction (p-value= -0.03) among 
patients with eGFRs ≥60 to <30 or on chronic dialysis. 
Receiving rt-PA therapy was associated with a weighted relative risk of 0.81 (99% CI 
0.61 to 1.08) in eGFR ≥60, 1.07 (99% CI 0.78 to 1.45) in eGFR 30-59, and 0.78 (99% CI 
0.38 to 1.58) in eGFR <30 or on chronic dialysis compared to those who did not receive 
rt-PA therapy (Figure 3). When we compared the weighted relative risk of dying in-
hospital comparing patients on their use of rt-PA therapy by eGFR category ≥60 vs. 30-
59 and vs. <30 or chronic dialysis, we did not find significant interaction.  
The percentage of death at 30 days and 1-year among those who received rt-PA were 
higher than the in-hospital findings but the trend across eGFR categories was similar 
(Figure 2d-e). Compared to those with an eGFR ≥60 who received rt-PA, patients with an 
eGFR 30-59 and <30 or on chronic dialysis and received rt-PA had statistically higher 
frequency of 30 day and 10-year death (standardized difference >21%). Positive additive 
interaction was found comparing death among those with an eGFR ≥60 vs. 30-59 and 
negative additive interaction was found comparing eGFR ≥60 vs. <30 or on chronic 
dialysis at 30 days and 1-year.  
Receiving rt-PA therapy was associated with similar weighted relative risks of death 
compared to those who did not receive rt-PA at 30 days and 1-year to the in-hospital risks 
estimates (Figure 3). When we estimated the weighted relative risk of death at 30 days 
and 1-year comparing patients on their use of rt-PA therapy by eGFR category (≥60 vs. 
30-59, ≥60 vs. <30 or chronic dialysis), we did not find a significant interaction. The 
exception was the relative risk of 1-year death comparing rt-PA usage among patients 
with an eGFR ≥60 to 30-59 (interaction p-value 0.01). The E-values estimating the 
strength of the relative risk association that an unmeasured confounder would need to 







Figure 1. Cohort build flow diagram 
Adults presenting to the hospital with an acute 
ischemic stroke
n = 44,659
The number of subjects after data cleaning 
exclusions and linking administrative datasets
n= 43,608
Number of subjects included in final analysis
n= 22,409
Excluded (n= 1,051 patients)
- Misaligned emergency department or admission dates
- Missing or invalid ICES Key Number (IKN)
- Missing or invalid age 
- Missing or invalid sex
- Non-Ontario resident 
Evidence of death before the index date (n= 102)
Missing serum creatinine (n= 6,754)
Missing international normalized ratio (INR) (n= 3,664)
Missing time from hospital arrival to imaging (n= 3,728)
Missing glucose (n= 534)
History of hemi, para or quardraplegia (n= 976)
Received care at a non-designated hospital (n= 4,058)
In-hospital stroke (n= 791)
Restrict to first ischemic stroke event (n= 592)
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Table 2. Acute ischemic stroke characteristics according to recombinant tissue plasminogen activator (rt-PA) therapy by estimated 
glomerular filtration rate (eGFR) category 
  
eGFR ≥60  
mL/min/1.73m2 
eGFR 30-59  
mL/min/1.73m2 
eGFR <30 mL/min/1.73m2 or  
chronic dialysis 
 Total rt-PA No rt-PA Total rt-PA No rt-PA Total rt-PA No rt-PA 
 N N (%) N (%) N N (%) N (%) N N (%) N (%) 
rt-PA therapy status 13,214 2,374 (18.0%) 10,840 (82.0%) 7,735 1,429 (18.5%) 6,306 (81.5%) 1,460 210 (14.4%) 1,250 (85.6%) 
Acute stroke characteristics and healthcare utilization 
Presented to Regional 
Stoke Centre† 10,569 1,857 (17.6%) 8,712 (82.4%) 6,317 1,175 (18.6%) 5,142 (81.4%) 1,162 174 (15.0%) 988 (85.0%) 
Presented to District 
Stroke Centre† 2,645 517 (19.5%) 2,128 (80.5%) 1,418 254 (17.9%) 1,164 (82.1%) 298 36 (12.1%) 262 (87.9%) 
Stroke symptoms at hospital presentation 
Weakness 10,529 2,233 (21.2%) 8,296 (78.8%) 6,406 1,373 (21.4%) 5,033 (78.6%) 1,187 204 (17.2%) 983 (82.8%) 
Speech disturbance 1,853 432 (23.3%) 1,421 (76.7%) 1,495 338 (22.6%) 1,157 (77.4%) 271 48 (17.7%) 223 (82.3%) 
Sensory symptoms 3,741 642 (17.2%) 3,099 (82.8%) 1,590 325 (20.4%) 1,265 (79.6%) 275 48 (74.5%) 227 (82.5%) 
Dysphagia 1,041 212 (20.4%) 829 (79.6%) 774 166 (21.4%) 608 (78.6%) 134 16 (11.9%) 118 (88.1%) 
Monocular blindness 288 56 (19.4%) 232 (80.6%) 157 45 (28.7%) 112 (71.3%) 24 6 (25.0%) 18 (75.0%) 
Field defect 1,421 452 (31.8%) 969 (68.2%) 932 292 (31.3%) 640 (68.7%) 185 55 (29.7%) 130 (70.3%) 
Other cognitive 
symptoms‡ 2,089 326 (15.6%) 1,763 (84.4%) 1,494 228 (15.3%) 1,266 (84.7%) 320 30 (9.4%) 290 (90.6%) 
Brainstem or cerebellar 
signs 3,159 407 (12.9%) 2,752 (87.1%) 1,481 182 (12.3%) 1,299 (87.7%) 265 25 (9.4%) 240 (90.6%) 
Headache or seizure 2,272 274 (12.1%) 1,998 (87.9%) 842 79 (9.4%) 763 (90.6%) 141 15 (10.6%) 126 (89.4%) 
Time from symptom onset to hospital arrival (hours) 
  Median (25th, 75th  
  percentiles) 
5 (1-17) 1 (1-2) 8 (2-22) 3 (1-14) 1 (1-2) 6 (2-17) 4 (1-15) 1 (1-2) 6 (2-18) 
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  <4.5 hours 6,483 2,293 (35.4%) 4,190 (64.6%) 4204 1,389 (33.0%) 2,815 (67.0%) 751 208 (27.7%) 543 (72.3%) 
  ≥4.5 hours 6,582 47 (0.7%) 6,535 (99.3%) 3,429 21 (0.6%) 3,408 (99.4%) 682 0 (0.0%) 682 (100.0%) 
Time of day           
  12am-<8am 1,584 262 (16.5%) 1,322 (83.5%) 828 117 (14.1%) 711 (85.9%) 139 17 (12.2%) 122 (87.8%) 
  8am-<5pm 8,000 1,342 (16.8%) 6,658 (83.2%) 4,519 764 (16.9%) 3,755 (83.1%) 851 111 (13.0%) 740 (87.0%) 
  5pm-<12am 3,629 770 (21.2%) 2,859 (78.8%) 2,388 548 (22.9%) 1,840 (77.1%) 470 82 (17.4%) 388 (82.6%) 
Time from hospital arrival to imaging            
  Median (25th, 75th  
  percentiles) (minutes) 
74 (30-178) 24 (14-36) 100 (42-206) 65 (28-163) 25 (16-37) 90 (37-190) 72 (30-180) 25 (15-32) 89 (37-204) 
   <3.5 hours 10,533 2,336 (22.2%) 8,197 (77.8%) 6,306 1,408 (22.3%) 4,898 (77.7%) 1,153 207 (18.0%) 946 (82.0%) 
National Institutes of Health Stroke Scale (NIHSS)§       
  Median (25th, 75th  
  percentiles) 
5 (2-10) 11 (7-16) 4 (1-8) 6 (2-13) 13 (8-18) 5 (2-11) 7 (3-14) 15 (9-19) 6 (2-12) 
  Uncaptured stroke 
signs/symptoms  
  (0) 
1887 16 (0.8%) 1,871 (99.2%) 792 8 (1.0%) 784 (99.9%) 118  0 (0.0%) 118 (100.0%) 
  Minor stroke (1-4) 
4338 232 (5.3%) 4,106 (94.7%) 2238 98 (4.4%) 2,140 (95.6%) 394 13 (3.3%) 381 (96.7%) 
  Moderate stroke (5-15) 
5153 1,405 (27.3%) 3,748 (72.7%) 3080 778 (25.3%) 2,302 (74.7%) 591 98 (16.6%) 493 (83.4%) 
  Moderate to severe  
  stroke (16-20) 
1140 490 (43.0%) 650 (57.0%) 988 347 (35.1%) 641 (64.9%) 198 59 (29.8%) 139 (70.2%) 
  Severe stroke (21-42) 416 199 (47.8%) 217 (52.2%) 407 187 (45.9%) 220 (54.1%) 85 39 (45.9%) 46 (54.1%) 
Laboratory measurements, median (25th, 75th percentiles) 























normalized ratio 1 (1-1) 1 (1-1) 1 (1-1) 1 (1-1) 1 (1-1) 1 (1-1) 1 (1-1) 1 (1-1) 1 (1-1) 
† Institution types include 1) District stroke centre: A facility that has written stroke protocols for emergency services, emergency department and acute care including: transport 
and triage protocols; ability to offer thrombolytic therapy, timely computed tomography scanning and expert interpretation; clinicians with stroke expertise; and linkages to 
rehabilitation and secondary prevention; and 2) Regional stroke centre: A facility that has all the requirements of a district stroke centre, plus neurosurgical facilities and 
interventional radiology; non-designated hospital: An acute hospital that does not fit the definition or a district or regional stroke centre.   
‡ Other cognitive symptoms refer to any deficits in memory, judgment, attention, or reasoning, and include personality changes.   
§ National Institutes of Health Stroke Scale (NIHSS) is a measure of stroke-related neurological deficit and severity is categorized as 0: No stroke symptoms, 1-4: Minor stroke, 5-
15: Moderate stroke, 16-20: Moderate to severe stroke or 21-42: Severe stroke.  
 
Missingness was not reported for weakness, dysphagia, monocular blindness, other cognitive symptoms, seizure, headache, sensory symptoms, rt-PA route of administration. time 
of day, time from hospital arrival to imaging, and time from hospital arrival to rt-PA due to cells less than or equal to five. In accordance with ICES privacy policies, cell sizes less 
than or equal to five cannot be reported.   











eGFR <30/chronic dialysis 
mL/min/1.73m2 
 2,374 1,429 210 
 N % N % N % 
Time from hospital arrival to rt-PA      
  Median (IQR) (minutes) 68 (51-92) 70 (53-92) 75 (56-96) 
  <3.5 hours 2,288 96.4% 1,390 97.3% 203 96.7% 
  ≥3.5 to  ≤4.5 hours 68 2.9% 34 2.4% 6 2.9% 
rt-PA Route of administration       
Intravenous (IV) 2,211 93.1% 1,379 96.5% 204 97.1% 
Intravenous (IV) dose, mg       
  Median (25th, 75th percentile) 68 (58-79) 63 (54-73) 63 (54-72) 
Intra-arterial (IA) dose, mg       




Table 4. Tissue plasminogen activator (rt-PA) therapy eligibility assessment based on ICES research and administrative databases 
 Exclusion present Exclusion absent 
rt-PA treatment exclusions N % N % 
1 Symptom onset to rt-PA therapy >4.5 hours  10,971 49.0% 11,438 51.0% 
2 History of intracranial hemorrhage in previous 6 months 17 0.1% 22,392 99.9% 
3 Stroke or serious head trauma or spinal trauma in last 3 months 95 0.4% 22,314 99.6% 
4 Recent major surgery, such as cardiac, thoracic abdominal or orthopedic 1,064 4.7% 21,345 95.3% 
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Stroke symptoms due to another non-ischemic acute neurological condition such as 
seizures with post-ictal Todd’s paralysis or focal neurological signs due to severe 
hypo- or hyperglycemia 
0 0.0% 22,409 100.0% 
6 Hypertension (blood pressure >185/110) 4,265 19.0% 18,144 81.0% 
7 Blood glucose concentration below 2.7 mmol/L or above 22.22 mmol/L 227 1.0% 22,182 99.0% 
8 International Normalized Ratio (INR) > 1.7 1,134 5.1% 21,275 94.9% 
9 Platelet count <100,000 per cubic millimeter 6 0.0% 22,403 100.0% 
10 
Any hemorrhage on computerized tomography (CT) or magnetic resonance imaging 
(MRI) 
158 0.7% 22,251 99.3% 
11 Mild stroke  7,593 33.9% 14,816 66.1% 
12 Severe stroke  1,373 6.1% 21,036 93.9% 
13 Anticoagulant 14 days prior to stroke onset 1,779 7.9% 20,630 92.1% 
14 Gastrointestinal bleed or urologist visit in previous 21 days 375 1.7% 22,034 98.3% 
15 Pregnant or has delivered within 6 weeks of symptom onset 14 0.1% 22,395 99.9% 
(1) Exclusions were based on eligibility criteria from the original tissue plasminogen activator randomized control trails36,40 and the Canadian Stroke Best Practice 
Recommendations46 for acute thrombolytic therapy. 
(2) Exclusions defined using the Ontario Stroke Registry with “unable to determine” or missing answer types were coded as ineligible. 
(3) Patients with missing laboratory values for platelets in the Gamma Dynacare dataset were coded as eligible. 
(4) Patients across criteria are not unique, that is, an individual can contribute to >1 criterion. 
(5) The following criteria could not be captured using ICES databases: a) Any other condition that could increase the risk of hemorrhage after tPA administration; b) Elevated 
partial thromboplastin time; c) CT showing early signs of extensive infarction, represented by a score of less than five on the Alberta Stroke Program Early CT Score [ASPECTS], 
or MRI showing an infarct volume greater than 150 cc on diffusion-weighted imaging; d) Arterial puncture at a non-compressible site in last 7 days; e) Rapidly improving 






Table 5. Crude baseline patient characteristics by recombinant tissue plasminogen activator (rt-PA) treatment status and estimated 






eGFR <30 mL/min/1.73m2 
or on chronic dialysis 
 rt-PA No rt-PA Std 
Diff* 
rt-PA No rt-PA Std 
Diff* 
rt-PA No rt-PA Std 
Diff*  1,049 1,662 670 959 161 131 
Characteristic N % N % % N % N % % N % N % % 
Demographics & characteristics at index 
Age                
  Median (25th, 75th percentile) 71 (59-80) 67 (57-77)  80 (73-86) 82 (75-88)  81 (74-87) 84 (78-89)  
  18-59 269 25.6% 516 31.0% 12% 35 3.6% 19 2.8% 5% 7 5.3% 6 3.7% 8% 
  60-79 497 47.4% 810 48.7% 3% 435 45.4% 238 35.5% 20% 53 40.5% 46 28.6% 25% 
  80+ 283 27.0% 336 20.2% 16% 487 50.8% 413 61.6% 22% 70 53.4% 109 67.7% 30% 
Sex, female 426 40.6% 690 41.5% 2% 542 56.5% 398 59.4% 6% 83 63.4% 91 56.5% 14% 
Income quintile                
  1 - Lowest 266 25.4% 353 21.2% 10% 200 20.9% 177 26.4% 13% 28 21.4% 40 24.8% 8% 
  2 201 19.2% 352 21.2% 5% 196 20.4% 139 20.7% 1% 27 20.6% 36 22.4% 4% 
  3 207 19.7% 339 20.4% 2% 173 18.0% 114 17.0% 3% 24 18.3% 22 13.7% 13% 
  4 175 16.7% 317 19.1% 6% 187 19.5% 131 19.6% 0% 25 19.1% 34 21.1% 5% 
  5 - Highest 196 18.7% 297 17.9% 2% 203 21.2% 104 15.5% 15% 26 19.8% 27 16.8% 8% 
Rural residence 117 11.2% 205 12.3% 3% 109 11.4% 68 10.1% 4% 11 8.4% 16 9.9% 5% 
Pre-event residence                
  Home 798 76.1% 1343 80.8% 11% 767 80.0% 469 70.0% 23% 100 76.3% 109 67.7% 19% 
  Other† 25 2.4% 17 1.0% 11% 17 1.8% 39 5.8% 21% 9 6.9% 8 5.0% 8% 
Pre-event independence‡                
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  Independent 381 36.3% 919 55.3% 39% 424 44.2% 161 24.0% 44% 27 16.8% 47 35.9% 44% 
  Slight to severe disability  145 13.8% 142 8.5% 17% 149 15.5% 161 24.0% 21% 50 38.2% 36 22.4% 35% 
  Missing 523 49.9% 601 36.2% 28% 386 40.3% 348 51.9% 23% 48 36.6% 84 52.2% 32% 
National Institutes of Health 
Stroke Scale (NIHSS)§, Median 
(25th, 75th percentile) 
7 (4-12) 11 (7-16)  12 (8-17) 8 (4-14)  14 (8-19) 10 (5-15)  
Comorbidities 
Estimated glomerular filtration 
rate  
79 (69-91) 80 (69-91)  48 (41-54) 48 (40-54)  24 (20-28) 23 (18-27)  
Charlson Comorbidity Index                 
  0 423 40.3% 899 54.1% 28% 337 35.1% 163 24.3% 24% 28 21.4% 21 13.0% 22% 
  1 263 25.1% 452 27.2% 5% 289 30.1% 195 29.1% 2% 26 19.8% 24 14.9% 13% 
  2 153 14.6% 164 9.9% 14% 149 15.5% 145 21.6% 16% 23 17.6% 37 23.0% 13% 
  ≥3 210 20.0% 147 8.8% 32% 184 19.2% 167 24.9% 14% 54 41.2% 79 49.1% 16% 
HASBLED Score                
  Median (25th, 75th percentile) 2 (1-3) 2 (1-2)  3 (2-3) 3 (2-4)  3 (3-4) 3 (3-4)  
  High bleeding risk ≥3 278 26.5% 295 17.7% 21% 506 52.8% 373 55.7% 6% 113 86.3% 147 91.3% 16% 
Chronic dialysis 0 0.0% 0 0.0% 0% 0 0.0% 0 0.0% 0% 11 8.4% 20 12.4% 13% 
Stroke 201 19.2% 207 12.5% 18% 163 17.0% 165 24.6% 19% 27 20.6% 36 22.4% 4% 
Transient ischemic attack 136 13.0% 143 8.6% 14% 111 11.6% 125 18.7% 20% 16 12.2% 25 15.5% 10% 
Atrial fibrillation 147 14.0% 237 14.3% 1% 218 22.7% 164 24.5% 4% 30 22.9% 44 27.3% 10% 
Coronary artery disease 237 22.6% 323 19.4% 8% 289 30.1% 208 31.0% 2% 44 33.6% 63 39.1% 11% 
Congestive heart failure 55 5.2% 61 3.7% 7% 94 9.8% 112 16.7% 20% 29 22.1% 32 19.9% 5% 
Diabetes mellitus 234 22.3% 263 15.8% 17% 215 22.4% 183 27.3% 11% 48 36.6% 65 40.4% 8% 
Hypertension 626 59.7% 936 56.3% 7% 763 79.6% 531 79.3% 1% 112 85.5% 136 84.5% 3% 
Venous thromboembolism 24 2.3% 27 1.6% 5% 20 2.1% 10 1.5% 5% ≤5 3.8% 6 3.7% 14% 
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Gastrointestinal bleed 38 3.6% 15 0.9% 18% 22 2.3% 29 4.3% 11% ≤5 3.8% 10 6.2% 19% 
Hyperlipidemia 361 34.4% 636 38.3% 8% 437 45.6% 290 43.3% 5% 120 91.6% 141 87.6% 13% 
Liver disease 22 2.1% 34 2.0% 1% 16 1.7% 12 1.8% 1% ≤5 3.8% ≤5 0.6% 14% 
Peripheral vascular disease 52 5.0% 36 2.2% 15% 53 5.5% 44 6.6% 5% 11 8.4% 16 9.9% 5% 
Current smoker 225 21.4% 382 23.0% 4% 96 10.0% 70 10.4% 1% 17 13.0% 7 4.3% 31% 
Valvular heart disease 38 3.6% 61 3.7% 1% 49 5.1% 29 4.3% 4% 10 7.6% 22 13.7% 20% 
Valve replacement 18 1.7% 28 1.7% 0% 16 1.7% 14 2.1% 3% ≤5 3.8% 6 3.7% 8% 
Pre-event medications (14 days prior to stroke event) 
Antiplatelets 285 27.2% 366 22.0% 12% 278 29.0% 242 36.1% 15% 46 35.1% 64 39.8% 10% 
* Standardized difference (Std Diff) ≥10% representing a statistically significant result when comparing rt-PA exposure groups. Statistically significant values are bolded. 
† Other pre-event residence includes nursing home, long-term care, retirement home, in-patient rehabilitation, complex continuing care, other acute, other emergency department 
and other (e.g. homeless).  
‡ The level of dependence definition in the Ontario Stroke Registry is based on the patient’s ability to manage activities of daily living (ADL) prior to their stroke event. 
Independence: Patient is fully independent in all ADLs and instrumental ADLs (IADL); Slight Disability: Patient is fully independent in all ADLs but is unable to carry out all 
IADLs; Moderate Disability: Patient requires help for some ADLs but remains ambulatory (with or without a cane or walker) without the assistance of another person; Moderately 
Severe Disability: Patient is unable to perform some of their ADLs, is unable to walk but can be left alone for several hours without supervision; Severe Disability: Patient is 
bedridden, incontinent and requires constant nursing care.  
§ National Institutes of Health Stroke Scale (NIHSS) is a measure of stroke-related neurological deficit and severity is categorized as 0: No stroke symptoms, 1-4: Minor stroke, 5-
15: Moderate stroke, 16-20: Moderate to severe stroke, or 21-42: Severe stroke.  
Missingness was not reported for income quintile, rural residence, pre-event residence, weakness, dysphagia, monocular blindness, other cognitive symptoms, seizure, and 





Table 6. Among patients eligible to receive recombinant tissue plasminogen activator (rt-PA), weighted baseline characteristics for 






eGFR <30 mL/min/1.73m2 
or on chronic dialysis 
 rt-PA No rt-PA Std 
Diff* 
rt-PA No rt-PA Std 
Diff* 
rt-PA No rt-PA Std 
Diff*  402 402 246 246 <32 <32 
Characteristic N % N % % N % N % % N % N % % 
Demographics & characteristics at index 
Age                
  Median (25th, 75th percentile) 69 (57-79) 69 (57-79)  81 (74-87) 81 (73-87)  83 (77-89) 84 (76-90)  
  60-79 189 47.1% 189 47.1% 0% 101 41.1% 101 41.1% 0% 9 30.6% 9 30.6% 0% 
  80+ 93 23.1% 93 23.1% 0% 137 55.5% 137 55.5% 0% 19 65.0% 19 65.0% 0% 
Sex, female 172 42.9% 166 41.3% 3% 140 56.9% 143 58.3% 3% 18 62.8% 18 62.8% 0% 
Income quintile                
  1 - Lowest 91 22.7% 91 22.7% 0% 60 24.3% 60 24.3% 0% ≤5 17.9% ≤5 17.9% 0% 
  2 77 19.3% 77 19.3% 0% 52 20.9% 52 20.9% 0% 7 24.9% 7 24.9% 0% 
  3 83 20.7% 83 20.7% 0% 43 17.3% 43 17.3% 0% ≤5 16.0% ≤5 16.0% 0% 
  4 73 18.3% 73 18.3% 0% 48 19.6% 48 19.6% 0% ≤5 17.8% ≤5 17.8% 0% 
  5 - Highest 76 18.8% 76 18.8% 0% 44 17.9% 44 17.9% 0% 6 22.2% 6 22.2% 0% 
Rural residence 57 14.3% 51 12.7% 5% 31 12.6% 27 10.9% 5% ≤5 11.8% ≤5 11.8% 0% 
Pre-event residence                
  Home 305 76.0% 305 76.0% 0% 186 75.4% 186 75.4% 0% 21 72.8% 21 72.8% 0% 
  Other† 94 23.3% 94 23.3% 0% 60 24.2% 60 24.2% 0% 6 20.7% 6 20.7% 0% 
Pre-event independence‡                
  Independent 178 44.3% 178 44.3% 0% 80 32.5% 80 32.5% 0% 7 25.1% 7 25.1% 0% 
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  Slight to severe disability 51 12.7% 51 12.7% 0% 55 22.3% 55 22.3% 0% 10 34.5% 10 34.5% 0% 
  Missing 172 42.9% 172 42.9% 0% 112 45.4% 112 45.4% 0% 12 40.2% 12 40.2% 0% 
National Institutes of Health 
Stroke Scale (NIHSS)§, Median 
(25th, 75th percentile) 
9 (6-13) 9 (5-15)  10 (7-15) 11 (5-16)  10 (7-17) 11 (7-16)  
Comorbidities 
Estimated glomerular filtration 
rate 
80 (70-91) 79 (69-92)  48 (41-55) 49 (41-54)  23 (20-27) 24 (18-27)  
Charlson Comorbidity Index                
 ≤2 340 84.6% 340 84.6% 0% 185 75.2% 188 76.4% 3% 16 55.2% 16 55.2% 0% 
 ≥3 61 15.3% 61 15.3% 0% 61 24.8% 57 23.2% 4% 13 44.7% 13 44.7% 0% 
HASBLED Score                
  Median (25th, 75th percentile) 2 (1-2) 2 (1-2)  3 (2-3) 3 (2-3)  3 (3-4) 3 (3-4)  
  High bleeding risk ≥3 88 21.9% 86 21.4% 1% 130 52.8% 130 52.8% 0% 26 89.4% 26 89.4% 0% 
Chronic dialysis 0 0% 0 0% 0% 0 0% 0 0% 0% ≤5 6.9% ≤5 6.9% 0% 
Stroke 64 15.8% 64 15.8% 0% 52 21.1% 52 21.1% 0% ≤5 18.6% ≤5 18.6% 8% 
Transient ischemic attack 47 11.8% 47 11.8% 0% 39 15.8% 39 15.8% 0% ≤5 12.6% ≤5 12.6% 0% 
Atrial fibrillation 56 13.9% 59 14.7% 2% 55 22.3% 61 24.8% 6% 7 23.1% 7 23.1% 0% 
Coronary artery disease 80 20.0% 92 22.8% 7% 71 29.0% 71 29.0% 0% 11 36.3% 11 36.3% 0% 
Congestive heart failure 16 4.0% 15 3.8% 1% 34 13.8% 34 13.8% 0% 7 22.6% 7 22.6% 0% 
Diabetes mellitus 80 19.8% 80 19.8% 0% 64 26.0% 64 26.0% 0% 10 35.4% 10 35.4% 0% 
Hypertension 232 57.8% 235 58.4% 1% 194 78.9% 199 80.6% 4% 24 83.8% 24 83.8% 0% 
Venous thromboembolism 8 2.1% 11 2.7% 4% ≤5 1.9% ≤5 1.9% 0% ≤5 2.9% ≤5 2.9% 0% 
Gastrointestinal bleed 8 2.0% 8 2.0% 0% 8 3.4% 8 3.4% 0% ≤5 4.7% ≤5 4.7% 0% 
Hyperlipidemia 139 34.7% 139 34.7% 0% 111 45.1% 119 48.4% 7% 14 47.5% 14 47.5% 0% 
Liver disease 11 2.7% 8 1.9% 5% ≤5 1.8% ≤5 1.3% 4% 0 1.4% 0 1.4% 0% 
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Peripheral vascular disease 13 3.2% 13 3.2% 0% 16 6.4% 13 5.4% 4% ≤5 4.4% ≤5 4.4% 0% 
Current smoker 92 22.8% 92 22.8% 0% 25 10.3% 25 10.3% 0% ≤5 5.5% ≤5 5.5% 0% 
Valvular heart disease 16 4.0% 14 3.5% 3% 14 5.8% 11 4.5% 6% ≤5 9.6% ≤5 9.6% 0% 
Valve replacement 7 1.8% 10 2.4% 4% ≤5 1.5% ≤5 2.2% 5% ≤5 4.1% ≤5 4.1% 0% 
Pre-event medications (14 days prior to stroke event) 
Antiplatelets 99 24.7% 99 24.7% 0% 81 32.8% 81 32.8% 0% 10 34.4% 10 34.4% 0% 
* Standardized difference (Std Diff) ≥10% representing a statistically significant result when comparing rt-PA exposure groups. Statistically significant values are bolded. 
† Other pre-event residence includes nursing home, long-term care, retirement home, in-patient rehabilitation, complex continuing care, other acute, other emergency department 
and other (e.g. homeless).  
‡ The level of dependence definition in the Ontario Stroke Registry is based on the patient’s ability to manage activities of daily living (ADL) prior to their stroke event. 
Independence: Patient is fully independent in all ADLs and instrumental ADLs (IADL); Slight Disability: Patient is fully independent in all ADLs but is unable to carry out all 
IADLs; Moderate Disability: Patient requires help for some ADLs but remains ambulatory (with or without a cane or walker) without the assistance of another person; Moderately 
Severe Disability: Patient is unable to perform some of their ADLs, is unable to walk but can be left alone for several hours without supervision; Severe Disability: Patient is 
bedridden, incontinent and requires constant nursing care.  
§ National Institutes of Health Stroke Scale (NIHSS) is a measure of stroke-related neurological deficit and severity is categorized as 0: No stroke symptoms, 1-4: Minor stroke, 5-
15: Moderate stroke, 16-20: Moderate to severe stroke or 21-42: Severe stroke.  
Missingness was not reported for income quintile, rural residence, pre-event residence, weakness, dysphagia, monocular blindness, other cognitive symptoms, seizure and 
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Figure 2a-e. Weighted percentage of outcomes by recombinant tissue plasminogen activator (rt-PA) therapy and estimated glomerular 






































* Ninety-nine percent confidence intervals were used to account for multiplicity, therefore p-values ≤ 0.01 are considered statistically significant. 
† Patients who died prior to hospital discharge were removed from the modified Rankin Scale (mRS) analyses. 




Chapter 5  
5 Discussion 
5.1 Ischemic stroke characteristics according to rt-PA 
therapy, treatment characteristics and the variation by 
eGFR category 
In our cohort of 22,409 patients presenting to the hospital with ischemic stroke we found 
that patients were treated with rt-PA similarly across eGFR categories ≥60 and 30-59 
(18% to 19%), but only 14% of those with an eGFR <30 mL/min/1.73m2 or on chronic 
dialysis received rt-PA therapy. Greater than 82% of the ischemic stroke population 
across categories of eGFR did not receive rt-PA therapy. At first glance it would appear 
that those with an eGFR <30 or on chronic dialysis do not receive rt-PA similarly to other 
eGFR categories. However, these data do not consider rt-PA eligibility. When we 
assessed each patient’s eligibility and restricted the cohort to only those eligible to 
receive rt-PA, we found that the proportion of those receiving rt-PA increased as eGFR 
declined from 39% in those ≥60 to 55% in those <30 or on chronic dialysis. Therefore, 
the declining usage of rt-PA therapy in the total acute ischemic cohort is misleading.  
Among those who received rt-PA, most (>96%) were treated within 3.5 hours of stroke 
symptom onset and there were no significant differences in the medians across eGFR 
categories. Of those who received rt-PA, a patient’s kidney function did not seem to be a 
barrier to their time to receiving therapy even though patients with severely decreased 
kidney function or kidney failure can be medically complex. Furthermore, those with 
reduced renal function exhibited higher NIHSS scores indicating a more severe 
presentation of stroke symptoms. Unsurprisingly, patients who received rt-PA had a 
higher median NIHSS score than controls.  
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5.2 rt-PA eligibility among patients with ischemic stroke  
We used research and administrative data to quantify a patient’s eligibility to receive rt-
PA therapy at the time of hospital presentation for an ischemic stroke in order to limit 
bias when comparing patients who did and did not receive rt-PA. Many patients were 
found to be ineligible for rt-PA therapy based on hospital arrival time >4.5 hours after 
symptom onset and this aligns with the documented reason rt-PA was not administered in 
the patient hospital medical record. Additionally, unmanaged blood pressure and 
anticoagulant use was frequently a criterion that indicated ineligibility. Other studies have 
attempted to estimate a patient’s eligibility to receive rt-PA using retrospective data with 
the intent of understanding how rt-PA treatment could be increased in the ischemic stroke 
population.97–100 Delay in arrival time was also found to be the most common avoidable 
exclusion across these studies.  
We found that 21% of ischemic stroke patients were potentially eligible to receive rt-PA 
and the frequency of therapy was similar across eGFR categories (range 20% to 21%). 
International estimates show an increased rate of rt-PA therapy use for all patients with 
ischemic stroke over time ranging from 1% to 7% between 2003 and 2010.101–103 One 
reason the frequency of rt-PA treatment is much higher in our study is because we 
excluded non-designated stroke centres. When included, the percentage of patients with 
ischemic stroke administered therapy in Ontario was 4% in 2004/05 and 12% in 
2012/13.104 This suggests that the eligibility criteria we used is missing some factor(s) 
that drive real-world rt-PA utilization in the province. 
When we compared those who were eligible for rt-PA using the database-based definition 
with those who received rt-PA therapy in the real-world we found moderate agreement 
(reliability). This is likely due, in part, to the subjective nature of clinical decision making 
despite having the best practice recommendations as guidelines. A physician and patient 
weigh multiple factors into their decision to treat with rt-PA and this is difficult to 
capture in a comprehensive manner. Additionally, there were several criteria that we 
could not capture in ICES databases and this may have contributed to the performance. 
Most notably is “…any condition that could increase the risk of hemorrhage after rt-PA 
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administration” which is highly subjective. These findings may suggest that the real-
world decision-making process relies on additional factors outside of the eligibility 
criteria which are likely patient- and physician-centered.  
5.3 Risk of secondary ICH by rt-PA exposure within 
categories of eGFR 
Using overlap weighting on the propensity score, we found that the weighted relative risk 
of secondary ICH was almost four times higher among those who received rt-PA 
compared to those who did not within eGFR categories ≥60 or 30-59 mL/min/1.73m2 
(relative risk and odds ratio estimates). In a meta-analysis of the rt-PA RCTs, Wardlaw et 
al. found that the odds ratio of symptomatic ICH within 7 days of rt-PA administration 
was 3.72 (95% CI 2.98 to 4.64) in the group who received rt-PA up to 6 hours after 
hospital arrival compared to controls.40 However, in the group of patients who received 
rt-PA within 3 hours of arrival, the pooled odds ratio of symptomatic ICH was 4.55 (95% 
CI 2.92 to 7.09). The smaller magnitude of secondary ICH risk found in our study could 
be due to differences in case mix which occurs frequently when comparing observational 
studies to RCTs; usually the general population includes a more diverse and complicated 
profile of baseline comorbidities but we restricted our analysis to those eligible for rt-PA 
therapy based on the trials and the best practice recommendations. These criteria are quite 
comprehensive and more stringent than what was included in the original trials. This 
potentially gives some indication that the guidelines may reduce the risk of secondary 
ICH in the eGFR ≥60 population, and perhaps among those with an eGFR <60. An 
additional consideration is that we were unable to distinguish symptomatic secondary 
ICH in both exposure groups which resulted in including asymptomatic secondary ICH in 
our definition. These hemorrhages are clinically less relevant and could contribute to the 
difference in estimates between studies. 
The rt-PA trials and our study sample sizes are relatively small and therefore it is difficult 
to estimate the true strength of secondary ICH risk, particularly among those with an 
eGFR <30. In a secondary analysis, Gensicke et al. compared a subgroup of their 
observational cohort (N= 1,427) by rt-PA exposure and eGFR. They found a higher odds 
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ratio of symptomatic ICH treated with rt-PA compared to those without rt-PA treatment 
among those with normal (≥60 mL/min/1.73m2) and low (<60 mL/min/1.73m2) eGFR, 
5.31 (95% CI 2.3 to 12.1) and 21.3 (95% CI 4.9 to 99.0), respectively, when adjusting for 
age and NIHSS.75 This analysis did not account for a patients eligibility to receive rt-PA, 
i.e. excluding those who, in the real-world would not likely receive rt-PA from the 
control group. To our knowledge, other data stratifying the rt-PA-secondary ICH 
association by eGFR category is not available elsewhere.  
We found that compared to those who did not receive rt-PA therapy, those who did had a 
significantly higher relative risk of secondary ICH and the magnitude of this relative risk 
was higher among those with an eGFR 30-59. From a biological standpoint, there is 
evidence to suggest that the coagulant gradient is modified by eGFR, although the 
mechanism behind it is not well established.52,105,106 There have been a number of 
hypotheses regarding the mechanisms that could contribute to an increased risk of 
secondary ICH including platelet dysfunction, other thrombus mechanics80,106, and 
endothelial dysfunction such as white matter disease.73,77 To date, there is no published 
data investigating the biological factors associated with rt-PA activity in the CKD 
population.52 Observational studies have shown an overall increased systemic bleeding 
risk by eGFR category compared to those with normal to high eGFR, among patients on 
chronic dialysis, and in kidney transplant recipients.53,55,63 When we look at the trend in 
the weighted percentage of secondary ICH comparing rt-PA therapy to controls across 
eGFR categories it is not significant and the frequency of bleeds is relatively stable (14% 
to 15%). We tested the weighted relative risk estimates across eGFR categories for 
interaction, i.e. a difference in weighted relative bleeding risk by rt-PA therapy status at 
different levels of kidney function, and did not find a statistically significant difference 
when comparing those with an eGFR ≥60 to those 30-59 mL/min/1.73m2. Put differently, 
the weighted relative risk of secondary ICH between those who received rt-PA therapy 
compared to controls is not statistically different across the eGFR categories reported. 
This finding is interesting in light of the observational literature on symptomatic ICH in 
the CKD population who received rt-PA. A meta-analysis of symptomatic ICH among 
those who received rt-PA and had CKD (eGFR ≥60 vs. <60) found the pooled OR to be 
1.56 (95% CI 1.05 to 2.33).77 The largest observational study to date (n= 44,410), which 
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was not included in the meta-analysis, found an adjusted odds ratio  estimate of 1.0 (95% 
CI 0.91 to 1.10) comparing those with and without reduced kidney function.78 Therefore, 
the estimates of secondary ICH after rt-PA therapy in the observational literature is 
conflicting among those with CKD. Our study also did not find a significant difference in 
the relative risk of rt-PA therapy compared to control between those with high to mildly 
decreased (≥60 mL/min/1.73m2) and moderately to severely decreased (30-59 
mL/min/1.73m2) kidney function and the E-value for these estimates were quite high 
(>4.6). Unfortunately, we are lacking the power to show the relative risk among those 
with an eGFR <30 or on chronic dialysis.  
5.4 Disability at hospital discharge  
We found that the weighted relative risk of being discharged alive and independent was 
up to two times higher among patients who received rt-PA therapy compared to controls 
(relative risk and odds ratio estimates). This protective relative effect increased as eGFR 
declined, recognizing that there are a low number of events in the lowest eGFR category. 
In the rt-PA RCT meta-analysis they also observed that use of rt-PA vs. control was 
associated with a greater chance of leaving the hospital alive and independent (OR 1.17, 
95% CI 1.06 to 2.38) up to 6 hours after receiving rt-PA, and 1.56 (95% CI 1.28 to 1.90) 
up to 3 hours after receiving rt-PA.40 Compared to our eGFR ≥60 group (ORw 1.62, 99% 
CI 1.08 to 2.41), this study provides additional evidence of a benefit in receiving rt-PA 
therapy in terms of functional status at discharge, which increases as eGFR declines. 
Furthermore, our E-value estimate would suggest an unmeasured confounder would need 
a relative risk of 2.01 to completely explain away our estimated effect (eGFR ≥60 
category). The most benefit appears to be among the eGFR <30 or on chronic dialysis 
(RRw 2.11) even though the NIHSS scores in the weighted cohort were similar across all 
rt-PA and control groups (scores ranging from 9 to 11, i.e. moderate stroke severity). 
Gensicke et al. estimated the odds ratio of a poor outcome defined as mRS 3-6 at 3 
months in a subgroup analysis in an observational study. When comparing those by tr-PA 
status with low eGFR (<60 mL/min/1.73m2), they found that the adjusted odds ratio of 
poor outcome were higher (1.79, 95% CI 1.41 to 2.25) among those who received rt-PA 
than controls. Those with normal eGFR (60 to 120 mL/min/1.73m2) who received rt-PA 
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had lower adjusted odds ratio of a poor outcome (0.77, 95% CI 0.63 to 0.94) than 
controls.75 As mentioned previously, these results were only adjusted for age and NIHSS 
and a patient’s eligibility for rt-PA was not considered.  
In the interaction analysis comparing the weighted relative risk across eGFR categories 
we found no statistically significant differences in the relative risk estimates. However, 
among those who received rt-PA it is clear that the risk of being discharged alive and 
independent is different for someone within an eGFR ≥60 compared to <30 or on chronic 
dialysis.  There is a dose response relationship; as eGFR declined the weighted rt-PA 
therapy groups less frequently observed a good outcome when comparing patients with 
similar exposure status. Obviagele et al. found a similar trend across eGFR categories 
among those who received rt-PA; as kidney function declined, the percentage of 
disability at discharge increased.78 This graded relationship is not unique to stroke and 
has also been shown in studies estimating the risk of major hemorrhage, death, and 
cardiovascular disease.53,56,107,108 The pooled estimate of poor outcome in Jung et al. 
found no difference between those with an eGFR ≥60 compared to <60 (OR 1.16, 95% 
CI 0.95 to 1.43) but noted that there was significant heterogeneity across studies.77 The 
remainder of the observational studies report disability by kidney function (eGFR ≥60 vs. 
<60) in the rt-PA population and provide conflicting estimates of the odds ratio of a poor 
outcome (mRS 2-6 or 3-6).68,70,75,76,82,109 
5.5 Death in-hospital, 30 days and 1-year  
We found that 9%, 15% and 18% of patients with an eGFR of ≥60, 30-59 and <30 
mL/min/1.73m2 or on chronic dialysis, respectively, died in-hospital after rt-PA treatment 
compared to 12%, 14% and 23% of those who did not receive rt-PA (weighted). Within 
eGFR categories, there was no difference in the relative risk of in-hospital death between 
those who received rt-PA therapy and those who did not. In the meta-analysis of the rt-
PA clinical trials, they found the odds ratio of death after 7 days from rt-PA therapy to be 
0.93 (95% CI, 0.73 to 1.18) among those treated with rt-PA within 3 hours compared to 
controls.40 Our weighted odds ratio estimate (0.79, 99% CI 0.44 to 1.43) shows a 
comparable odds ratio of death. Patients with ischemic stroke in our weighted cohort had 
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a similar median hospital length of stay across eGFR categories, 7 to 8 days, and most 
were treated within 3.5 hours of symptom onset. We found the magnitude of benefit to be 
greater, but our weighted estimates produced a low number of events which may be a 
contributing factor to this difference. It should be noted that Wardlaw et al. cited 
significant heterogeneity across RCTs for the death outcomes.40 As previously 
mentioned, our study eligibility criteria are more extensive than the trails and this may 
also contribute to the lower death estimates.  
As the number of events increased in our 30 day and 1-year death estimates, most eGFR 
categories exhibited no difference in the relative risk of death in these extended time 
intervals across eGFR categories. Wardlaw et al.’s meta-analysis results for long-term 
death (trials ranged from 4 weeks to 6 months) found a pooled odds ratio of 1.06 (95% CI 
0.94 to 1.20).40 Most of our results were not statistically significant, though most were in 
favour of rt-PA therapy within categories of eGFR, i.e. the relative risk and odds ratio of 
death was lower among those who received rt-PA and had comparable kidney function. 
For all death endpoints, our interaction estimates of the differences in relative risk 
between exposure groups suggest that, for the most part, those that receive rt-PA therapy, 
and those that do not, do similarly across eGFR categories. However, the overall risk of 
death is not the same for someone who received rt-PA with an eGFR ≥60 to an eGFR 
<30 mL/min/1.73m2 or on chronic dialysis. Obviagele et al. found that the adjusted odds 
ratio of in-hospital death among those that received rt-PA by eGFR category increased as 
kidney function declined, ranging from 1.09 (95% CI 0.97 to 1.22) (eGFR ≥60) and 2.07 
(95% CI 1.59 to 2.69) (eGFR <15).78 Observational data comparing those who received 
rt-PA therapy by their kidney function (≥60 vs. <60 mL/min/1.73m2) found mixed results 
on the odds ratio of death (in-hospital and 3 months). In a meta-analysis comparing 
patients with eGFR ≥60 vs. <60, the pooled odds ratio of death (in-hospital and 3 month) 
among those who received rt-PA was 1.70 (95% CI 1.03 to 2.81) but they reported 




We recognize that there are some study limitations. First, the gold standard for estimating 
the safety and efficacy of rt-PA by kidney function should be done using an RCT design 
but this is unlikely due to costs for a relatively small population and ethical 
considerations in light of the potential benefit. Instead we used propensity score and the 
overlap weighting method to mimic aspects of an RCT design and to adjust for 
confounding due to extreme differences between exposure groups. Despite this, there is 
still some level of residual confounding in our estimates. We used the E-value to assess 
the degree of confounding to which the results would be altered and most of our 
estimates were robust.  
Second, some of the ICES databases we used were not created for the purposes of 
research, e.g. the Discharge Abstract Database and the Registered Persons Database, and 
this may result in residual and unmeasured confounding as administrative data is limited 
by the information collected. That said, the Ontario Stroke Registry, of which most of our 
study was based, was created with the intent of enriching the administrative stroke care 
data in Ontario for the purpose of research and monitoring and should reduce the amount 
of information bias and residual confounding.  
Third, attempting to estimate a patient’s eligibility to receive rt-PA proved to be 
challenging and restricted our sample size. Although many of the eligibility criteria, from 
RCTs and the Canadian Stroke Best Practice Guidelines, were quantifiable using research 
and administrative data, the reliability of database-based eligibility was moderate when 
compared against real-world use of rt-PA therapy. Therefore, misclassification bias may 
be present when attempting to categorize rt-PA eligibility. There were six eligibility 
criteria that we were not able define using administrative data. This could result in some 
misclassification for the propensity to receive rt-PA therapy and alter our estimates of the 
outcomes of rt-PA vs. no rt-PA.  
We cannot make inferences about the entire ischemic stroke population in Ontario 
because our cohort does not include those who received care at a non-designated 
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(community) hospital or those not included in the in the Ontario Stroke Audit sample. 
Furthermore, our sample size declines with eGFR as does the precision of our estimates 
and this impacts the strength of understanding of the outcomes among patients with 
severely decreased function and kidney failure.  
5.7 Interpretation 
We found a high relative risk of secondary ICH among those who received rt-PA 
compared to those who did not in eGFR categories ≥60 and 30-59 mL/min/1.73m2. 
However, those who received rt-PA were more likely to be alive and independent 
compared to controls within all eGFR categories. This benefit increased as eGFR 
declined. Compared to those who received rt-PA within eGFR categories, the relative risk 
of death was almost always higher for who did not. Recognizing that we had a small 
sample/events in the eGFR <30 or on chronic dialysis group which impacts the precision 
of these estimates for all outcomes. Generally, the benefits (less disability and death) and 
risks (secondary ICH) of rt-PA therapy compared to controls are similar when comparing 
those with an eGFR ≥60 to other categories of eGFR except death at 1-year where eGFR 
is 30-59 mL/min/1.73m2. Therefore, a patient’s kidney function may not impact how rt-
PA therapy performs compared to controls with similar kidney function. However, the 
frequency of an outcome across eGFR categories appears to be markedly different when 
comparing those with normal kidney function (≥60 mL/min/1.73m2) to those with 
reduced kidney function (<60 mL/min/1.73m2) with the same exposure (i.e. received rt-
PA therapy). Differences in the risk of our outcomes across eGFR may be more strongly 
associated with kidney function than rt-PA therapy; additional research to understand this 
relationship is necessary. A large multi-centre RCT to further investigate the safety and 
efficacy of rt-PA in the chronic kidney disease population who suffer an ischemic stroke 
would provide better estimates of treatment effects but may never be done.  
5.8 Generalizability 
We restricted our analysis to those who received care at a Regional or District Stroke 
Centre in Ontario so our findings may not be applicable to those that receive care in non-
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designated facilities. However, the majority of patients with an acute stroke in the 
province access care at either a Regional or District Stroke Centre. The multivariable 
analysis was restricted to those who were eligible to receive rt-PA based on research and 
administrative databases which was found to have moderate agreement. Furthermore, 
these findings would not extend to those who do not meet the recommended criteria for 
receiving rt-PA. These findings may not be generalizable to other ischemic stroke 
populations in other regions due differences in populations.  
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2021 (the “Effective Date”) between the Heart and Stroke Foundation of 
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B. The Licensee wishes to obtain a license to use the Licensor Work in the 
appendix of its master’s thesis and Licensor has agreed to grant such a 
license, subject to the terms and conditions of this Agreement. 
 
In consideration of the mutual covenants and conditions contained herein, 
the sufficiency of which are hereby acknowledged, the Parties agree as 
follows: 
 
1. GRANT of LICENSE 
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to Licensee a perpetual, non-exclusive, royalty free, non-transferable 
license (the “License”) to use and reproduce the Licensor Work, in 
digital format, for inclusion in the appendix of the Licensee’s master’s 
thesis only (the “Purpose”). 
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of the Licensor Work, or any other Licensor intellectual property, to 
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2.1. Title of Materials: Box 5B Criteria for Acute Thrombolytic Therapy 
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Work; 
b) the Licensor Work does not infringe any Canadian trademarks, 
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copyrights or other intellectual property rights; 
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Attn: Dominique Mongeon, Intellectual Property 
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Student, MSc candidate  
1151 Richmond Street London, Ontario N6A 3K7 
Any such notice shall be deemed effective: 
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9. GENERAL PROVISIONS 
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electronic transmission and the counterparts together shall constitute an 
original. 
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Appendix B. Checklist of recommendations for reporting of observation studies using the Reporting of studies Conducted using 
Observational Routinely-collected health Data (RECORD) Statement 
 
Item No STROBE items RECORD items Reported 
Title and abstract 1 
(a) Indicate the study's design with a 
commonly used term in the title or the 
abstract.  
(b) Provide in the abstract an informative and 
balanced summary of what was done and 
what was found. 
(1.1) The type of data used should be 
specified in the title or abstract. When 
possible, the name of the databases used 
should be included. 
(1.2) If applicable, the geographic region 
and time frame within which the study 
took place should be reported in the title 
or abstract.  
(1.3) If linkage between databases was 
conducted for the study, this should be 
clearly stated in the title or abstract. 
Title page 
Introduction     
Background/ rationale 2 
Explain the scientific background and 
rationale for the investigation being reported.  
 Introduction 
Objectives 3 
State specific objectives, including any 




Methods     
Study design 4 
Present key elements of study design early in 
the paper.  
 Methods 
Setting 5 
Describe the setting, locations, and relevant 
dates, including periods of recruitment, 
exposure, follow-up, and data collection.  
 Methods 
Participants 6 
(a) Give the eligibility criteria, and the 
sources and methods of selection of 
participants. Describe methods of follow-up.   
(b) For matched studies, give matching 
criteria and number of exposed and 
unexposed. 
(6.1) The methods of study population 
selection (such as codes or algorithms 
used to identify subjects) should be listed 
in detail. If this is not possible, an 
explanation should be provided.  
(6.2) Any validation studies of the codes 
or algorithms used to select the 
population should be referenced. If 
validation was conducted for this study 
and not published elsewhere, detailed 
methods and results should be provided. 
 (6.3) If the study involved linkage of 
databases, consider use of a flow diagram 
or other graphical display to demonstrate 
the data linkage process, including the 
number of individuals with linked data at 





Clearly define all outcomes, exposures, 
predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if 
applicable. 
(7.1) A complete list of codes and 
algorithms used to classify exposures, 
outcomes, confounders, and effect 
modifiers should be provided. If these 
cannot be reported, an explanation should 
be provided. 
Methods 
Data sources/   
  measurement 
8 
For each variable of interest, give sources of 
data and details of methods of assessment 
(measurement). Describe comparability of 




Describe any efforts to address potential 
sources of bias. 
 Methods 
Study size 10 Explain how the study size was arrived at.  Methods 
Quantitative variables 11 
Explain how quantitative variables were 
handled in the analyses. If applicable, 
describe which groupings were chosen and 
why. 
 Methods 
Statistical methods 12 
(a) Describe all statistical methods, including 
those used to control for confounding.  
(b) Describe any methods used to examine 




(c) Explain how missing data were addressed.  
(d) If applicable, explain how loss to follow-
up was addressed.  
(e) Describe any sensitivity analyses. 
Data access and cleaning methods  N/A 
(12.1) Authors should describe the extent 
to which the investigators had access to 
the database population used to create the 
study population. 
(12.2) Authors should provide 
information on the data cleaning methods 
used in the study.  
Methods 
Linkage  N/A 
(12.3) State whether the study included 
person-level, institutional-level, or other 
data linkage across two or more 
databases. The methods of linkage and 
methods of linkage quality evaluation 
should be provided.  
Methods 
Results     
Participants 13 
(a) Report numbers of individuals at each 
stage of study--e.g. numbers potentially 
eligible, examined for eligibility, confirmed 
(13.1) Describe in detail the selection of 
the persons included in the study (i.e., 




eligible, included in the study, completing 
follow-up, and analyzed.  
(b) Give reasons for non-participation at each 
stage. 
(c) Consider use of a flow diagram. 
filtering based on data quality, data 
availability, and linkage. The selection of 
included persons can be described in the 
text and/or by means of the study flow 
diagram. 
Descriptive data 14 
(a) Give characteristics of study participants 
(e.g. demographic, clinical, social) and 
information on exposures and potential 
confounders.  
(b) Indicate number of participants with 
missing data for each variable of interest.  
(c) Summarize follow-up time (e.g. average 
and total amount).  
 Results 
Outcome data 15 
Report numbers of outcome events or 
summary measures over time. 
 Results 
Main results 16 
(a) Give unadjusted estimates and, if 
applicable, confounder-adjusted estimates 
and their precision (e.g. 95% confidence 
interval). Make clear which confounders were 




(b) Report category boundaries when 
continuous variables were categorized. 
(c) If relevant, consider translating estimates 
of relative risk into absolute risk for a 
meaningful time period.  
Other analyses 17 
Report other analyses done (e.g. analyses of 
subgroups and interactions, and sensitivity 
analyses). 
 Results 
  Key results 18 
Summarize key results with reference to 
study objectives. 
 Discussion 
  Limitations 19 
Discuss limitations of the study, taking into 
account sources of potential bias or 
imprecision. Discuss both direction and 
magnitude of any potential bias. 
(19.1) Discuss the implications of using 
data that were not created or collected to 
answer the specific research question(s). 
Include discussion of misclassification 
bias, unmeasured confounding, missing 
data, and changing eligibility over time, 
as they pertain to the study being 
reported.  
Discussion 
  Interpretation 20 
Give a cautious overall interpretation of 
results considering objectives, limitations, 
multiplicity of analyses, results from similar 




  Generalizability 21 
Discuss the generalizability (external 
validity) of the study results. 
 Discussion 
Other information    
Funding 22 
Give the source of funding and the role of the 
funders for the present study and, if 
applicable, for the original study on which the 
present article is based. 
 Discussion 
Accessibility of protocol, raw data, and 
programming code 
 N/A 
(22.1) Authors should provide 
information on how to access any 
supplemental information such as the 
study protocol, raw data, or programming 
code.  
Appendices  




Appendix C. Ontario Stroke Registry sampling strategies 
The Ontario Stroke Audit (OSA) is a population-based chart abstraction project that 
occurs approximately every two years that started in 2002 and continued until 2013. Each 
audit year, a random sample of patients visiting an emergency department or who are 
admitted with a suspected stroke or transient ischemic attack are generated at ICES based 
on International Classification of Disease 10th version Canadian edition (ICD-10-CA) 
codes and each patient’s medical record is audited based on this case list. The Regional 
Stroke Centre data consisted of prospective and retrospective data collection at the 
regional facilities between 2001 and 2012. One hundred percent the suspected stroke and 
TIA cases were captured at participating centres.  
The sampling strategies for each audit and stroke centre data collection year are as 
follows: 
Fiscal Year 
Regional Stroke Centre 
Sampling Strategy 
Ontario Stroke Audit  
Sampling Strategy 
2001/2002 Prospective chart abstraction 
at 21 sites. 
 





No OSA data collection 
2002/03 Prospective chart abstraction 
at 24 sites. 
 
20 stroke centres and 4 
Telestroke sites. 
All Ontario hospitals with >10 
stroke admissions in a year. 
 











20% random sample selected from 
all eligible cases 
 
N=3,534 
2004/05 Hybrid of prospective and 
retrospective chart abstraction. 
 
10 stroke centres and 3 
Telestroke sites.  
 
All suspected stroke and 
transient ischemic attack 
events.  
All Ontario hospitals with >10 
stroke admissions in a year. 
 
Pediatric and psychiatric hospitals 
were excluded 
 
20% random sample selected from 
all eligible cases 
 
N=5,032 
2008/09 Hybrid of prospective and 
retrospective chart abstraction. 
 
10 stroke centres and 3 
Telestroke sites.  
 
All suspected stroke and 
transient ischemic attack 
events. 
All Ontario hospitals with >10 
stroke admissions in a year. 
 
Pediatric and psychiatric hospitals 
were excluded 
 
20% random sample selected from 
all eligible cases 
 
N=4,363 
2010/11 Hybrid of prospective and 
retrospective chart abstraction. 
 
All Ontario acute care hospitals 





10 stroke centres and 3 
Telestroke sites.  
 
All suspected stroke and 
transient ischemic attack 
events. 
Psychiatric hospitals were 
excluded.  
 
100% of eligible events at 
designated stroke centres and 
Telestroke sites, and a 30% 
random sample of eligible cases at 
all other non-designated sites. 
 
N=14,540 
2012/13 Hybrid of prospective and 
retrospective chart abstraction. 
 
10 stroke centres and 3 
Telestroke sites.  
 
All suspected stroke and 
transient ischemic attack 
events. 
All Ontario hospitals with >30 
stroke admissions in a year. 
 
Pediatric and psychiatric hospitals 
were excluded.  
 
100% of eligible events at 
designated stroke centres and 
Telestroke sites, and a 50% 
random sample at high-volume 
non-designated sites (>100 cases 
per year) and 30% random sample 
at low-volume non-designated 






Appendix D. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
Equation 
The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation88 for 
converting serum creatinine to estimated glomerular filtration rate: 
 
CKD-EPI =141 x min (Scr/κ, 1)α x max (Scr/κ, 1)-1.209 x 0.993Age x 1.018 [if Female] x 
1.159 [if African American] 
Where:  
κ = 0.7 for females and 0.9 for males,   
α = -0.329 for females and -0.411 for males,  
min = the minimum of Scr/κ or 1,  
max = the maximum of Scr/κ or 1.  
 
 
NOTE: Race component of the formula was not used for the analyses, as race is not 






Appendix E. Precision of kidney function measurements 
We tested the agreement of baseline estimated glomerular filtration rate (eGFR) found in 
the OSR at the time of the acute ischemic stroke to outpatient eGFR found in other 
laboratory sources (Gamma Dynacare Medical Laboratories) to determine whether acute 
eGFR after an ischemic stroke is a good approximation of stable eGFR. First, serum 
creatinine (SCr) from both databases were converted to eGFR using the CKD-EPI 
equation (Appendix C). We established stable kidney function in the outpatient 
population by requiring evidence of at least two outpatient eGFR values for each patient 
separated by ≥3 months to <1 year and within 5 mL/min/1.73m2 or ≤5% of each 
other.1,110 The mean value of these two results was used to represent stable outpatient 
kidney function. We then found the first hospital-based eGFR value done at the time of 
the acute stroke, within 7 and 365 days of the most recent prior outpatient eGFR value. 
The distribution of eGFRs was calculated by inpatient and outpatient status. All the 
eGFRs were then sorted into KIDGO kidney function categories. We calculated percent 
agreement, Cohen’s kappa statistic, and p-values, along with corresponding 95% 
confidence intervals. A Bland-Altman plot was also generated to assess agreement 
between to two groups within eGFR categories.  
Results  
Of the 20,409 patients with ischemic stroke in our cohort, 478 had evidence of kidney 
function defined as two outpatient SCr laboratory values separated by ≥3 months to 1 
year, within 5 mL/min/1.73m2 or ≤ 5% of each other. The median (25th, 75th percentiles) 
eGFR among those with an inpatient and median of mean outpatient eGFR was 56 
(39,75) and 59 (43,81), respectively. There were 384 instances of agreement and 94 
instances of disagreement within eGFR categories. Agreement was defined as both eGFR 
measurements in the same KIDGO category (≥60, 30-59, <30 mL/min/1.73m2). When we 
calculated the percent agreement of mean outpatient versus inpatient eGFR, we found 
that 80% (95% CI 77 to 84) of laboratory tests agreed within categories of KDIGO 
eGFR. When we calculated the weighted kappa, we found substantial agreement between 
inpatient and mean outpatient eGFR values (0.71, 95% CI 0.66 to 0.77). Finally, we 
assessed the two methods of eGFR measurement using the Pearson’s correlation 
78 
 
coefficient and a Bland-Altman correlation plot. We found that inpatient and mean 
outpatient eGFR are equally precise (Pearson’s correlation coefficient= -0.03, p-value= 
0.49) and reasonable agreement based on visual inspection of the Bland-Altman 
correlation plot (Figure E1).  
Figure E1. Bland-Altman correlation plot testing the agreement between inpatient and 





Appendix F. Baseline characteristic concept definitions 
Variable Database Variable/Codes 
Age Ontario Stroke Registry 
(OSR) 
AGE 
Sex OSR SEX 
Residential status RPDB PSTLYEAR 
Residence type OSR ER_REGISTRYARRFROM 
Index year OSR FYEAR 
Institution type OSR OSACLASS 
 
Time from symptom onset to 
hospital arrival (mins) 
OSR ER_HOSPARRIVAL 
 




Time from hospital arrival to 








Serum creatinine (SCr) 











rt-PA therapy status OSR 
 
EI_THROMBOLYSIS 


























OSR EI_IVDOSE  
EI_IADOSE 




SD_DYSARTHRIA SD_DYSPHAGIA SD_MONOCBLIND 

































Diastolic BP (DBP) (mm HG) OSR 
 
EI_DBP 















Hyperlipidemia  OSR 
 
PMH_HYPERLIPIDEMIA 
Smoking history OSR 
 
PMH_SMOKERTYPE 
History of stroke OSR 
 
PMH_STROKE 











Peripheral vascular disease OSR 
 
PMH_PERIPHERALDISEASE 
Atrial fibrillation or flutter OSR 
 
PMH_ATRIALFIB 
Valvular heart disease OSR 
 
PMH_VALVULAR 
Valve replacement OSR 
 
PMH_VALVE 
Venous thromboembolism OSR 
 
PMH_DEEPVEIN 
Coronary artery disease OSR 
 
PMH_CAD 
GI bleed OSR 
 
PMH_GIBLEED 




 Acute care  
International Classification of Disease (ICD) 9th version: 4561, 
4562, 070, 5722, 5723, 5724, 5728, 573, 7824, V026, 571, 2750, 












 Emergency Department 
visits 






ICD10: B16, B17, B18, B19, I85, R17, R18, R160 R162, B942, 
Z225, E831, E830, K70, K713, K714, K715, K717, K721, K729, 
K73, K74, K753, K754, K758, K759, K76, K77 
 
Ontario Health Insurance Plan (OHIP) fee: Z551, Z554 
 
OHIPdx: 571, 573, 070 













Anticoagulant prior to stroke 
event 
OSR  
















Appendix G. Determining the presence of acute kidney injury at admission  
To estimate the proportion of acute kidney injury (AKI) in our acute stroke inpatient population we captured patient’s inpatient SCr 
for their acute stroke event and an outpatient SCr within 7 and 365 days prior.111,112 A single outpatient SCr was used because we 
found the SCr laboratory measurements to be a stable measure of kidney function in our cohort. Patients with an eGFR <15 
mL/min/1.73m2 or on chronic dialysis were removed from this analysis. Patients were classified into KIDGO categories of AKI, 
which groups patients into three stages (1 to 3) or no AKI based on a change from their outpatient to inpatient SCr.113  
Results  
Starting with the kidney function precision cohort (n=478) we excluded 12 patients based on kidney function <15 mL/min/1.73m2 or 
on chronic dialysis. We found that most patients with stroke (87%) did not have any evidence of AKI when presenting to their stroke 









Appendix H. Recombinant tissue plasminogen activator therapy eligibility criteria definitions  
The eligibility criteria we used was gathered based on a compilation of the Canadian Stroke Best Practice Recommendations Hyper-
acute ischemic stroke treatment and criteria used in the randomized controlled trials (RCT) of recombinant tissue plasminogen 
activator (rt-PA) versus control. All the criteria in the Canadian Stroke Best Practice Recommendations were incorporated if it was 
feasible to define within ICES databases. Criteria obtained from the RCTs was included if it was used in two or more trials.  
Study Criteria Sources 
Symptom onset to rt-PA therapy >4.5 hours  Canadian Stroke Best Practice 
Recommendations (CSBPR)46, 114–116  
History of intracranial hemorrhage in previous 6 months CSBPR46 
Stroke or serious head trauma or spinal trauma in last 3 months CSBPR46  
RCT114–120  
Recent major surgery, such as cardiac, thoracic, abdominal or orthopedic CSBPR46  
RCT114–120  
Stroke symptoms due to another non-ischemic acute neurological condition such 
as seizures with post-ictal Todd’s paralysis or focal neurological signs due to 
severe hypo- or hyperglycemia 
CSBPR46 





Blood glucose concentration below 2.7 mmol/L or above 22.22 mmol/L CSBPR46 
International Normalized Ratio (INR) > 1.7 CSBPR46 
Platelet count <100,000 per cubic millimeter CSBPR46 
Any hemorrhage on computerized tomography (CT) or magnetic resonance 
imaging (MRI) 
CSBPR46 
Mild stroke  RCT114–120  
Severe stroke  RCT114–120  
Anticoagulant prior to stroke onset RCT115,116,119,120  
Gastrointestinal bleed or urologist visit in previous 21 days RCT114–120  
Pregnant or has delivered within 6 weeks of symptom onset RCT114,116  
Canadian Stroke Best Practice recommendations that could not be measured using ICES data holdings: 
(1) “Any other condition that could increase the risk of hemorrhage after rt-PA administration”; 
(2) “Elevated partial thromboplastin time”; 
(3) “CT showing early signs of extensive infarction, represented by a score of less than five on the Alberta Stroke Program Early CT 
Score [ASPECTS], or MRI showing an infarct volume greater than 150 cc on diffusion-weighted imaging”; 
(4) “Arterial puncture at a non-compressible site in last 7 days”; and  




Appendix I. Covariates included in each Propensity Score model by estimated glomerular filtration rate (eGFR) category 
Covariates were included in the propensity score if the difference between tPA exposure groups was ≥10% 
≥60 mL/min/1.73m2 30-59 mL/min/1.73m2 
eGFR <30 mL/min/1.73m2 or  
chronic dialysis 
Age (Continuous/Categorical) Age (Continuous/Categorical) Age (Continuous/Categorical) 
Antiplatelet prescription CCI (Continuous) CCI (Continuous/Categorical) 
Charlson Comorbidity Score (CCI) 
(Continuous/Categorical) 
Cognitive (initial stroke symptoms) Diabetes Mellitus 
Diabetes Mellitus  Diabetes Mellitus DBP 
International normalized ratio (INR) HAS-BLED bleeding risk score 
(Continuous/Categorical) 
INR 
Systolic blood pressure (SBP) NIHSS Index year 
Index year Time from hospital arrival to first imaging 
(Continuous/Categorical) 
GI bleed 
HAS-BLED bleeding risk score 
(Continuous, quadratic) 
Speech (initial stroke symptoms) HAS-BLED bleeding risk score 
(Continuous/Categorical) 
Headache Stroke Hypertension 
Time from symptom onset to hospital 
arrival (Continuous) 
TIA Dialysis 
National Institute for Health Stroke Scale 
(NIHSS) 





Time from hospital arrival to first imaging 
(Continuous/Categorical) 
Pre-event dependence NIHSS 
Smoking status Monocular blindness (initial stroke 
symptoms) 
PVD 
Stroke Pre-event residence Time from hospital arrival to first imaging 
(Continuous/Categorical) 
Field defect (initial stroke symptoms) Seizure (initial stroke symptoms) Smoking status 
Pre-event dependence Weakness (initial stroke symptoms) Speech (initial stroke symptoms) 
Pre-event residence Arrival time (time of day) Brain symptoms (initial stroke symptoms) 
Weakness (initial stroke symptoms) Antiplatelet prescription  Income  
Cognitive symptoms (initial stroke 
symptoms) 
Congestive heart failure (CHF) Pre-event dependence 
Diastolic blood pressure (DBP) Index year Pre-event residence 
Gastrointestinal (GI) bleed GI bleed Weakness (initial stroke symptoms) 
Hyperlipidemia  Time from symptom onset to hospital 
arrival (Continuous/Categorical) 
Arrival time (time of day) 
Arrival time (time of day) Smoking status  Atrial fibrillation 
Income  Income  CHF 
Seizure (initial stroke symptoms) Coronary artery disease (CAD) Venous thromboembolism (VTE) 




Transient ischemic attack (TIA) Glucose Hyperlipidemia  
 Institution type  TIA 
 Sensory (initial stroke symptoms) Field defect (initial stroke symptoms) 
  Sex  
  Monocular blindness (initial stroke 
symptoms) 
  Valve replacement 
  Valvular heart disease 
  Antiplatelet prescription  
  Liver disease 
  SBP 
  Rural residence 
  Seizure (initial stroke symptoms) 
  Coronary artery disease 
  Cognitive (initial stroke symptoms) 
  Dysphagia (initial stroke symptoms) 
  Headache (initial stroke symptoms) 




Appendix J. Distribution of propensity scores pre- and post-overlap weighting 
across categories of estimated glomerular filtration rate 












































Appendix K. Reasons recombinant tissue plasminogen activator (rt-PA) was not given 
When analyzing the documented reasons that patients did not receive rt-PA (N=18,396), the top reason was that the patient arrived at 
the hospital too late after onset of symptoms (>55%), their ischemic stroke was too mild (>23%), followed by patient decision (<16%) 
(Table K1). Approximately 6.1% of patients who did not receive rt-PA did not have a reason documented. There were some 
significant differences across eGFR categories, reasons such as patient’s stroke too severe, contraindication to thrombolysis and 
physician decision were more frequent as eGFR declined.  
Table K1. Documented reasons recombinant tissue plasminogen activator (rt-PA) not given to patients with ischemic stroke by 
estimated glomerular filtration rate 
 
Estimated glomerular filtration rate  
mL/min per 1.73m2 
Standardized difference* 
 
≥60 30 to 59 
<30 or chronic 
dialysis 
≥60 vs.  
30 to 59 
≥60 vs. <30/ 
chronic dialysis 
Number of patients with ischemic stroke who did not receive 
rt-PA 
10,840 6,306 1,250 
  
Reasons  N (%) N (%) N (%) % % 
Patient too mild 3,645 (33.6) 1,868 (29.6) 289 (23.1) 9% 23% 
Patient too severe 357 (3.3) 403 (6.4) 103 (8.2) 14% 21% 
Patient arrived too late (>4 hours) 6,657 (61.4) 3,558 (56.4) 694 (55.5) 10% 12% 
Contraindication to thrombolysis 1,092 (10.1) 939 (14.9) 243 (19.4) 15% 26% 
Physician decision 972 (9.0) 734 (11.6) 202 (16.2) 9% 22% 




Delay in decision to treat despite (emergency department 
arrival <4 hours) 
287 (2.6) 175 (2.8) 43 (3.4) 1% 5% 
Other 1,079 (10.0) 725 (11.5) 170 (13.6) 5% 11% 
*Standardized difference ≥10% representing a statistically significant result when compared to patients with an eGFR ≥60 mL/min/1.73m2. Statistically significant values are 
bolded.  






Appendix L. Crude baseline characteristics by estimated glomerular filtration rate (eGFR) among a subgroup of patients 






eGFR <30 mL/min/1.73m2 
or on chronic dialysis 
 rt-PA No rt-PA Std 
Diff* 
rt-PA No rt-PA Std 
Diff* 
rt-PA No rt-PA Std 
Diff*  1,049 1,662 670 959 161 131 
Characteristic N % N % % N % N % % N % N % % 
Demographics 
Age                
  Median (25th, 75th percentile) 71 (59-80) 67 (57-77)  80 (73-86) 82 (75-88)  81 (74-87) 84 (78-89)  
  18-59 269 25.6% 516 31.0% 12% 35 3.6% 19 2.8% 5% 7 5.3% 6 3.7% 8% 
  60-79 497 47.4% 810 48.7% 3% 435 45.4% 238 35.5% 20% 53 40.5% 46 28.6% 25% 
  80+ 283 27.0% 336 20.2% 16% 487 50.8% 413 61.6% 22% 70 53.4% 109 67.7% 30% 
Sex, female 426 40.6% 690 41.5% 2% 542 56.5% 398 59.4% 6% 83 63.4% 91 56.5% 14% 
Income quintile                
  1 - Lowest 266 25.4% 353 21.2% 10% 200 20.9% 177 26.4% 13% 28 21.4% 40 24.8% 8% 
  2 201 19.2% 352 21.2% 5% 196 20.4% 139 20.7% 1% 27 20.6% 36 22.4% 4% 
  3 207 19.7% 339 20.4% 2% 173 18.0% 114 17.0% 3% 24 18.3% 22 13.7% 13% 
  4 175 16.7% 317 19.1% 6% 187 19.5% 131 19.6% 0% 25 19.1% 34 21.1% 5% 
  5 - Highest 196 18.7% 297 17.9% 2% 203 21.2% 104 15.5% 15% 26 19.8% 27 16.8% 8% 
Rural residence 117 11.2% 205 12.3% 3% 109 11.4% 68 10.1% 4% 11 8.4% 16 9.9% 5% 
Pre-event residence                
  Home 798 76.1% 1343 80.8% 11% 767 80.0% 469 70.0% 23% 100 76.3% 109 67.7% 19% 
  Other† 25 2.4% 17 1.0% 11% 17 1.8% 39 5.8% 21% 9 6.9% 8 5.0% 8% 




  Independent 381 36.3% 919 55.3% 39% 424 44.2% 161 24.0% 44% 27 16.8% 47 35.9% 44% 
  Slight to severe disability  145 13.8% 142 8.5% 17% 149 15.5% 161 24.0% 21% 50 38.2% 36 22.4% 35% 
  Missing 523 49.9% 601 36.2% 28% 386 40.3% 348 51.9% 23% 48 36.6% 84 52.2% 32% 
Acute stroke characteristics and healthcare utilization 
  Regional Stroke Centre 825 78.6% 1288 77.5% 3% 777 81.0% 533 79.6% 4% 103 78.6% 125 77.6% 2% 
  District Stroke Centre 224 21.4% 374 22.5% 3% 182 19.0% 137 20.4% 4% 28 21.4% 36 22.4% 2% 
Stroke symptoms at hospital presentation              
  Weakness  914 87.1% 1567 94.3% 25% 928 96.8% 615 91.8% 22% 126 96.2% 156 96.9% 4% 
  Speech disturbance 195 18.6% 295 17.7% 2% 207 21.6% 138 20.6% 2% 26 19.8% 33 20.5% 2% 
  Sensory Symptoms 461 27.7% 259 24.7% 7% 218 22.7% 112 16.7% 15% 30 22.9% 28 17.4% 14% 
  Dysphagia 97 9.2% 148 8.9% 1% 110 11.5% 83 12.4% 3% 12 9.2% 15 9.3% 0% 
  Monocular Blindness 13 1.2% 38 2.3% 8% 27 2.8% 7 1.0% 13% ≤5 3.8% 0 0.0% 17% 
  Field defect 96 9.2% 311 18.7% 28% 201 21.0% 72 10.7% 28% 32 24.4% 19 11.8% 33% 
  Other cognitive symptoms 177 16.9% 220 13.2% 10% 156 16.3% 151 22.5% 16% 19 14.5% 30 18.6% 11% 
  Brainstem or cerebellar signs 203 19.4% 277 16.7% 7% 123 12.8% 103 15.4% 7% 18 13.7% 21 13.0% 2% 
  Headache or seizure 165 15.7% 186 11.2% 13% 53 5.5% 53 7.9% 10% 3 2.3% 11 6.8% 22% 
Time from symptom onset to hospital arrival (hours) 
            
  Median (25th, 75th percentile) 
2 (1-3) 1 (1-2)  1 (1-2) 2 (1-3)  1 (1-2) 2 (1-3)  
  <3.5 hours 864 82.4% 1637 98.5% 57% 951 99.2% 563 84.0% 57% 130 99.2% 138 85.7% 53% 
Time of day                
  12am-<8am 139 13.3% 170 10.2% 10% 71 7.4% 76 11.3% 13% 11 8.4% 18 11.2% 9% 
  8am-<5pm 587 56.0% 946 56.9% 2% 520 54.2% 378 56.4% 4% 67 51.1% 87 54.0% 6% 




Time from hospital arrival to imaging  
            
  Median (25th, 75th percentile) 
(minutes) 
51 (26-124) 23 (13-35)  24 (15-36) 50 (24-109)  23 (15-31) 44 (27-96)  
  <3.5 hours 889 84.7% 1649 99.2% 55% 953 99.4% 603 90.0% 43% 131 100.0% 144 89.4% 49% 
National Institutes of Health 
Stroke Scale (NIHSS)§, Median 
(25th, 75th percentile) 
7 (4-12) 11 (7-16)  12 (8-17) 8 (4-14)  14 (8-19) 10 (5-15)  
Laboratory measurements, Median (25th, 75th percentile) 
Estimated glomerular filtration 
rate  
79 (69-91) 80 (69-91)  48 (41-54) 48 (40-54)  24 (20-28) 23 (18-27)  




147 (132-161)  150 (132-164) 150 (133-165)  144 (127-159) 145 (124-160)  
Diastolic blood pressure  80 (71-90) 81 (72-91)  78 (69-88) 77 (67-88)  74 (63-84) 72 (61-82)  
International normalized ratio  1 (1-1) 1 (1-1)  1 (1-1) 1 (1-1)  1 (1-1) 1 (1-1)  
Glucose  7 (6-8) 7 (6-8)  7 (6-8) 7 (6-8)  7 (6-10) 7 (6-9)  
Comorbidities 
Charlson Comorbidity Score                
  0 423 40.3% 899 54.1% 28% 337 35.1% 163 24.3% 24% 28 21.4% 21 13.0% 22% 
  1 263 25.1% 452 27.2% 5% 289 30.1% 195 29.1% 2% 26 19.8% 24 14.9% 13% 
  2 153 14.6% 164 9.9% 14% 149 15.5% 145 21.6% 16% 23 17.6% 37 23.0% 13% 
  3 210 20.0% 147 8.8% 32% 184 19.2% 167 24.9% 14% 54 41.2% 79 49.1% 16% 
HASBLED Score                
  Median (25th, 75th percentile) 2 (1-3) 2 (1-2)  3 (2-3) 3 (2-4)  3 (3-4) 3 (3-4)  
  High bleeding risk ≥3 278 26.5% 295 17.7% 21% 506 52.8% 373 55.7% 6% 113 86.3% 147 91.3% 16% 
Chronic dialysis 0 0.0% 0 0.0% 0% 0 0.0% 0 0.0% 0% 11 8.4% 20 12.4% 13% 
Stroke 201 19.2% 207 12.5% 18% 163 17.0% 165 24.6% 19% 27 20.6% 36 22.4% 4% 




Atrial fibrillation 147 14.0% 237 14.3% 1% 218 22.7% 164 24.5% 4% 30 22.9% 44 27.3% 10% 
Coronary artery disease 237 22.6% 323 19.4% 8% 289 30.1% 208 31.0% 2% 44 33.6% 63 39.1% 11% 
Congestive heart failure 55 5.2% 61 3.7% 7% 94 9.8% 112 16.7% 20% 29 22.1% 32 19.9% 5% 
Diabetes mellitus 234 22.3% 263 15.8% 17% 215 22.4% 183 27.3% 11% 48 36.6% 65 40.4% 8% 
Hypertension 626 59.7% 936 56.3% 7% 763 79.6% 531 79.3% 1% 112 85.5% 136 84.5% 3% 
Venous thromboembolism 24 2.3% 27 1.6% 5% 20 2.1% 10 1.5% 5% ≤5 3.8% 6 3.7% 14% 
Gastrointestinal Bleed 38 3.6% 15 0.9% 18% 22 2.3% 29 4.3% 11% ≤5 3.8% 10 6.2% 19% 
Hyperlipidemia 361 34.4% 636 38.3% 8% 437 45.6% 290 43.3% 5% 120 91.6% 141 87.6% 13% 
Liver disease 22 2.1% 34 2.0% 1% 16 1.7% 12 1.8% 1% ≤5 3.8% ≤5 0.6% 14% 
Peripheral vascular disease 52 5.0% 36 2.2% 15% 53 5.5% 44 6.6% 5% 11 8.4% 16 9.9% 5% 
Current smoker 225 21.4% 382 23.0% 4% 96 10.0% 70 10.4% 1% 17 13.0% 7 4.3% 31% 
Valvular heart disease 38 3.6% 61 3.7% 1% 49 5.1% 29 4.3% 4% 10 7.6% 22 13.7% 20% 
Valve replacement 18 1.7% 28 1.7% 0% 16 1.7% 14 2.1% 3% ≤5 3.8% 6 3.7% 8% 
Pre-event medications (14 days prior to stroke event) 
Antiplatelets 285 27.2% 366 22.0% 12% 278 29.0% 242 36.1% 15% 46 35.1% 64 39.8% 10% 
* Standardized difference (Std Diff) ≥10% representing a statistically significant result when comparing rt-PA exposure groups. Statistically significant values are bolded. 
† Other pre-event residence includes nursing home, long-term care, retirement home, in-patient rehabilitation, complex continuing care, other acute, other emergency department 
and other (e.g. homeless).  
‡ The level of dependence definition in the Ontario Stroke Registry is based on the patient’s ability to manage activities of daily living (ADL) prior to their stroke event. 
Independence: Patient is fully independent in all ADLs and instrumental ADLs (IADL); Slight Disability: Patient is fully independent in all ADLs but is unable to carry out all 
IADLs; Moderate Disability: Patient requires help for some ADLs but remains ambulatory (with or without a cane or walker) without the assistance of another person; Moderately 
Severe Disability: Patient is unable to perform some of their ADLs, is unable to walk but can be left alone for several hours without supervision; Severe Disability: Patient is 
bedridden, incontinent and requires constant nursing care.  
§ National Institutes of Health Stroke Scale (NIHSS) is a measure of stroke-related neurological deficit and severity is categorized as 0: No stroke symptoms, 1-4: Minor stroke, 5-
15: Moderate stroke, 16-20: Moderate to severe stroke, or 21-42: Severe stroke.  
Missingness was not reported for income quintile, rural residence, pre-event residence, weakness, dysphagia, monocular blindness, other cognitive symptoms, seizure, and 






Appendix M. Weighted baseline characteristics by estimated glomerular filtration rate (eGFR) among a subgroup of patients 






eGFR <30 mL/min/1.73m2 
or on chronic dialysis 
 rt-PA Control Std 
Diff* 
rt-PA Control Std 
Diff* 
rt-PA Control Std 
Diff*  402 402 246 246 <32 <32 
Characteristic N % N % % N % N % % N % N % % 
Demographics 
Age                
  Median (25th, 75th percentile) 69 (57-79) 69 (57-79)  81 (74-87) 81 (73-87)  83 (77-89) 84 (76-90)  
  60-79 189 47.1% 189 47.1% 0% 101 41.1% 101 41.1% 0% 9 30.6% 9 30.6% 0% 
  80+ 93 23.1% 93 23.1% 0% 137 55.5% 137 55.5% 0% 19 65.0% 19 65.0% 0% 
Sex, female 172 42.9% 166 41.3% 3% 140 56.9% 143 58.3% 3% 18 62.8% 18 62.8% 0% 
Income quintile                
  1 - Lowest 91 22.7% 91 22.7% 0% 60 24.3% 60 24.3% 0% ≤5 17.9% ≤5 17.9% 0% 
  2 77 19.3% 77 19.3% 0% 52 20.9% 52 20.9% 0% 7 24.9% 7 24.9% 0% 
  3 83 20.7% 83 20.7% 0% 43 17.3% 43 17.3% 0% ≤5 16.0% ≤5 16.0% 0% 
  4 73 18.3% 73 18.3% 0% 48 19.6% 48 19.6% 0% ≤5 17.8% ≤5 17.8% 0% 
  5 - Highest 76 18.8% 76 18.8% 0% 44 17.9% 44 17.9% 0% 6 22.2% 6 22.2% 0% 
Rural residence 57 14.3% 51 12.7% 5% 31 12.6% 27 10.9% 5% ≤5 11.8% ≤5 11.8% 0% 
Pre-event residence                
  Home 305 76.0% 305 76.0% 0% 186 75.4% 186 75.4% 0% 21 72.8% 21 72.8% 0% 
  Other† 94 23.3% 94 23.3% 0% 60 24.2% 60 24.2% 0% 6 20.7% 6 20.7% 0% 




  Independent 178 44.3% 178 44.3% 0% 80 32.5% 80 32.5% 0% 7 25.1% 7 25.1% 0% 
  Slight to severe disability 51 12.7% 51 12.7% 0% 55 22.3% 55 22.3% 0% 10 34.5% 10 34.5% 0% 
  Missing 172 42.9% 172 42.9% 0% 112 45.4% 112 45.4% 0% 12 40.2% 12 40.2% 0% 
Acute stroke characteristics and healthcare utilization 
  Regional Stroke Centre 321 79.7% 308 76.5% 8% 198 80.5% 198 80.5% 0% 22 74.9% 22 74.3% 1% 
  District Stroke Centre 81 20.3% 94 23.5% 8% 48 19.5% 48 19.5% 0% 7 25.1% 7 25.7% 1% 
Stroke symptoms at hospital presentation              
  Weakness  367 91.3% 367 91.3% 0% 230 93.4% 230 93.4% 0% 28 97.4% 28 97.4% 0% 
  Speech disturbance 74 18.4% 78 19.4% 3% 53 21.4% 53 21.4% 0% 6 20.4% 6 20.4% 0% 
  Sensory Symptoms 113 28.0% 97 24.2% 9% 45 18.3% 45 18.3% 0% ≤5 16.7% ≤5 16.7% 0% 
  Dysphagia 35 8.8% 38 9.4% 2% 26 10.4% 29 11.8% 4% ≤5 8.9% ≤5 8.9% 0% 
  Monocular Blindness 7 1.7% ≤5 1.3% 3% ≤5 1.7% ≤5 1.7% 0% 0 0.0% 0 0.0% 0% 
  Field defect 51 12.7% 51 12.7% 0% 40 16.1% 40 16.1% 0% ≤5 18.9% ≤5 18.9% 0% 
  Other cognitive symptoms 60 14.9% 60 14.9% 0% 47 19.2% 47 19.2% 0% 6 19.2% 6 19.2% 0% 
  Brainstem or cerebellar signs 67 16.6% 72 17.9% 3% 32 13.2% 35 14.2% 3% ≤5 9.7% ≤5 9.7% 0% 
  Seizure ≤5 0.8% ≤5 0.8% 0% ≤5 0.4% ≤5 0.4% 0% ≤5 1.9% ≤5 1.9% 0% 
  Headache 52 12.9% 52 12.9% 0% 12 4.9% 16 6.6% 7% ≤5 2.7% ≤5 2.7% 0% 
Time from symptom onset to hospital arrival (hours)             
  Median (25th, 75th percentile) 1 (1-2) 1 (1-2)  1 (1-2) 1 (1-2)  1 (1-2) 1 (1-2)  
  <3.5 hours 386 95.9% 378 94.1% 8% 241 97.7% 241 97.7% 0% 29 98.6% 29 98.6% 0% 
  ≥3.5 to <4.0 hours 11 2.8% 17 4.1% 7% 6 2.3% 6 2.3% 0% 0 1.4% 0 1.4% 0% 
  ≥4.0 to <4.5 hours ≤5 1.2% 7 1.8% 5% 0 0.0% 0 0.0% 0% 0 0.0% 0 0.0% 0% 




  12am-<8am 46 11.6% 46 11.6% 0% 23 9.3% 23 9.3% 0% - - - - - 
  8am-<5pm 225 55.9% 225 55.9% 0% 140 56.7% 140 56.7% 0% - - - - - 
  5pm-<12am 131 32.5% 131 32.5% 0% 84 33.9% 84 33.9% 0% - - - - - 
Time from hospital arrival to imaging              
  Median (25th, 75th percentile) 
(minutes) 
25 (14-37) 35 (20-71)  25 (16-37) 38 (21-70)  26 (17-42) 30 (20-44)  
  <3.5 hours 393 97.8% 393 97.8% 0% 243 98.7% 243 98.7% 0% 29 100.0% 29 100.0% 0% 
National Institutes of Health 
Stroke Scale (NIHSS)‖, Median 
(25th, 75th percentile) 
9 (6-13) 9 (5-15)  10 (7-15) 11 (5-16)  10 (7-17) 11 (7-16)  
Laboratory measurements, Median (25th, 75th percentile) 
Estimated glomerular filtration 
rate 
80 (70-91) 79 (69-92)  48 (41-55) 49 (41-54)  23 (20-27) 24 (18-27)  
Systolic blood pressure 147 (132-162) 147 (133-162)  150 (133-164) 148 (132-164)  146 (123-160) 143 (126-160)  
Diastolic blood pressure 82 (73-91) 82 (73-91)  77 (68-88) 77 (68-89)  72 (61-84) 71 (60-83)  
International normalized ratio 1 (1-1) 1 (1-1)  1 (1-1) 1 (1-1)  1 (1-1) 1 (1-1)  
Glucose 7 (6-8) 7 (6-8)  7 (6-9) 7 (6-9)  7 (6-10) 7 (6-10)  
Comorbidities 
Charlson Comorbidity Score                
 ≤2 340 84.6% 340 84.6% 0% 185 75.2% 188 76.4% 3% 16 55.2% 16 55.2% 0% 
 ≥3 61 15.3% 61 15.3% 0% 61 24.8% 57 23.2% 4% 13 44.7% 13 44.7% 0% 
HASBLED Score                
  Median (25th, 75th percentile) 2 (1-2) 2 (1-2)  3 (2-3) 3 (2-3)  3 (3-4) 3 (3-4)  
  High bleeding risk ≥3 88 21.9% 86 21.4% 1% 130 52.8% 130 52.8% 0% 26 89.4% 26 89.4% 0% 
Chronic dialysis 0 0% 0 0% 0% 0 0% 0 0% 0% ≤5 6.9% ≤5 6.9% 0% 




Transient ischemic attack 47 11.8% 47 11.8% 0% 39 15.8% 39 15.8% 0% ≤5 12.6% ≤5 12.6% 0% 
Atrial fibrillation 56 13.9% 59 14.7% 2% 55 22.3% 61 24.8% 6% 7 23.1% 7 23.1% 0% 
Coronary artery disease 80 20.0% 92 22.8% 7% 71 29.0% 71 29.0% 0% 11 36.3% 11 36.3% 0% 
Congestive heart failure 16 4.0% 15 3.8% 1% 34 13.8% 34 13.8% 0% 7 22.6% 7 22.6% 0% 
Diabetes mellitus 80 19.8% 80 19.8% 0% 64 26.0% 64 26.0% 0% 10 35.4% 10 35.4% 0% 
Hypertension 232 57.8% 235 58.4% 1% 194 78.9% 199 80.6% 4% 24 83.8% 24 83.8% 0% 
Venous thromboembolism 8 2.1% 11 2.7% 4% ≤5 1.9% ≤5 1.9% 0% ≤5 2.9% ≤5 2.9% 0% 
Gastrointestinal bleed 8 2.0% 8 2.0% 0% 8 3.4% 8 3.4% 0% ≤5 4.7% ≤5 4.7% 0% 
Hyperlipidemia 139 34.7% 139 34.7% 0% 111 45.1% 119 48.4% 7% 14 47.5% 14 47.5% 0% 
Liver disease 11 2.7% 8 1.9% 5% ≤5 1.8% ≤5 1.3% 4% 0 1.4% 0 1.4% 0% 
Peripheral vascular disease 13 3.2% 13 3.2% 0% 16 6.4% 13 5.4% 4% ≤5 4.4% ≤5 4.4% 0% 
Current smoker 92 22.8% 92 22.8% 0% 25 10.3% 25 10.3% 0% ≤5 5.5% ≤5 5.5% 0% 
Valvular heart disease 16 4.0% 14 3.5% 3% 14 5.8% 11 4.5% 6% ≤5 9.6% ≤5 9.6% 0% 
Valve replacement 7 1.8% 10 2.4% 4% ≤5 1.5% ≤5 2.2% 5% ≤5 4.1% ≤5 4.1% 0% 
Pre-event medications 
Antiplatelets 99 24.7% 99 24.7% 0% 81 32.8% 81 32.8% 0% 10 34.4% 10 34.4% 0% 
* Standardized difference (Std Diff) ≥10% representing a statistically significant result when comparing rt-PA exposure groups. Statistically significant values are bolded. 
† Other pre-event residence includes nursing home, long-term care, retirement home, in-patient rehabilitation, complex continuing care, other acute, other emergency department 
and other (e.g. homeless).  
‡ The level of dependence definition in the Ontario Stroke Registry is based on the patient’s ability to manage activities of daily living (ADL) prior to their stroke event. 
Independence: Patient is fully independent in all ADLs and instrumental ADLs (IADLs) Slight Disability: Patient is fully independent in all ADLs but is unable to carry out all 
IADLs; Moderate Disability: Patient requires help for some ADLs but remains ambulatory (with or without a cane or walker) without the assistance of another person; Moderately 
Severe Disability: Patient is unable to perform some of their ADLs, is unable to walk but can be left alone for several hours without supervision; Severe Disability: Patient is 
bedridden, incontinent and requires constant nursing care.  
§ Time of day data were not reported for eGFR <30 or on chronic dialysis due to cells less than or equal to five. In accordance with ICES privacy policies, cell sizes less than or 
equal to five cannot be reported.   
‖ National Institutes of Health Stroke Scale (NIHSS) is a measure of stroke-related neurological deficit and severity is categorized as 0: No stroke symptoms, 1-4: Minor stroke, 5-




Missingness was not reported for income quintile, rural residence, pre-event residence, weakness, dysphagia, monocular blindness, other cognitive symptoms, seizure, and 








Appendix N. Weighted effects of recombinant tissue plasminogen activator (rt-PA) within categories of estimated glomerular 





a. Secondary intracranial hemorrhage 











b. Modified Rankin Score (mRS) 0-2 
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